

Title page

Neonatal adaptation issues after maternal exposure to prescription drugs: withdrawal syndromes and residual pharmacological effects

Irma Convertino, PharmD,¹ Alice Capogrosso Sansone, PharmD,¹ Alessandra Marino, PharmD,¹ Maria T. Galiulo, PharmD,¹ Stefania Mantarro, PharmD,¹ Luca Antonioli, PhD,¹ Matteo Fornai, PhD,¹ Corrado Blandizzi, MD,^{1,2} Marco Tuccori, PhD²

¹ Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

² Unit of Adverse Drug Reaction Monitoring, University Hospital of Pisa, Pisa, Italy

Name and address for correspondence

Dr. Marco Tuccori, PhD
Tuscan Regional Centre for Pharmacovigilance
Unit of Adverse Drug Reaction Monitoring
University Hospital of Pisa
Via Roma, 55
I-56126 Pisa, Italy
Tel: +39-050-2218761
Fax: +39-050-992071
E-mail: m.tuccori@ao-pisa.toscana.it

Funding and Conflicts of Interest. No sources of funding were used to assist in the preparation of this article. Irma Convertino, Alice Capogrosso Sansone, Alessandra Marino, Maria Teresa Galiulo, Stefania Mantarro, Luca Antonioli, Matteo Fornai, Corrado Blandizzi and Marco Tuccori have no conflicts of interest that are directly relevant to the content of this review.

Abstract

Exposure to drugs during pregnancy has the potential of harming the offspring. Teratogenic effects are the most feared adverse outcomes in newborns. However, a wide spectrum of less known, usually reversible and often acute, neonatal adverse events can also occur due to drug intake by mothers during pregnancy and particularly in close proximity of the delivery. These effects can be explained by withdrawal syndromes caused by the delivery-related discontinuation of the drug disposition from the mother to the fetus, or by a residual pharmacological effect due to an accumulation of the drug in the blood and tissues of the newborn. Although these adverse reactions have been described mainly for abuse drugs, several prescription drugs have been also involved. These include mainly psychotropic medications such as opioids, antidepressants, antiepileptics and antipsychotics. With few exception, validated protocols for the assessment and management of withdrawal or residual pharmacological effects of these drugs in neonates are often lacking or incomplete. Spontaneous reporting of these adverse reactions seems limited, although it might represent a useful tool for improving our knowledge about drug-induced neonatal syndromes. This narrative review is aimed at the description of drugs and drug classes for which a licit maternal use in the pre-delivery period has been associated with neonatal non-teratogenic disorders. For each drug class, epidemiology, clinical features, biological mechanism and management of these adverse reactions have been discussed in detail.

Key points

- Newborns exposed in pregnancy to psychotropic drugs may experience neonatal syndromes, including neonatal withdrawal symptoms and/or residual pharmacological effect
- Psychotropic drugs most involved in neonatal adaptation issues are opioids, antidepressants, antiepileptics (including barbiturates and benzodiazepines), and antipsychotics

Introduction

It is well known that exposure during pregnancy to compounds endowed with pharmacologic activity has the potential of harming the offspring. Teratogenic effects are definitely the most feared adverse outcomes in newborns.[1] However, a wide spectrum of less known, usually reversible and often acute, adverse events can also occur in newborns due to drug intake by mothers during pregnancy and particularly in close proximity of the delivery. With some exceptions, the majority of these adverse events likely results from withdrawal syndromes. Indeed, the delivery determines a discontinuation of the drug intake that the baby was receiving from the mother. In the traditional Pharmacovigilance classification of adverse drug reactions, these events belong to the “E” (end of use) category.[2] In other settings, these effects may result from “residual” activities of drugs, particularly those endowed with long half-life (type “A” - augmented - adverse drug reactions).[2] In these settings, the immaturity of metabolic functions in newborns are likely to play an important role.[3] Early identification of the origin of symptoms is of primary importance for the appropriate management of newborns. Indeed, in case of withdrawal, the newborn may benefit from a reintroduction of the discontinued drug or its safer alternative within the same drug class; by contrast, in case of residual toxicity, being exposed further to the withdrawn drug may have detrimental effects on the newborn.[4]

Withdrawal symptoms have been extensively investigated since many years in drug-addicted pregnant women exposed to abuse substances. Nevertheless, some prescription drugs have been also reported to be associated with such events in neonates. Their clinical presentation is variable and usually includes several signs and symptoms ranging from behavioral abnormalities to neurological impairments. For this reason, these effects are usually defined as a syndrome, which is sometimes designated as “neonatal abstinence syndrome”,[5] “neonatal withdrawal syndrome”,[6] “neonatal adaptation syndrome”[7] or even “neonatal behavioral syndrome”[8] depending on the putative mechanism. In this narrative review, we will use the definition “neonatal abstinence syndrome” (NAS), which is the most frequently employed to describe withdrawal symptoms, making a distinction from other kind of events, which can be more likely explained by a residual pharmacological effect of the drug on the fetus or newborn.

Overall, based on the above background, this narrative review is aimed at the description of drugs and drug classes for which a licit maternal use in the pre-delivery period has been associated with neonatal non-teratogenic disorders. These disturbances have been reviewed and described in detail on the basis of currently available evidence.

Methods

English-language literature indexed in MEDLINE was explored without limits of time up to December 31st, 2015, using the terms “neonatal abstinence syndrome”, “neonatal withdrawal syndrome”, “neonatal behavioral

syndrome” and “neonatal adaptation syndrome”. Since there is no standard clinical definition for this syndrome, case reports dealing with neonatal behavioral and neurological alterations after exposure to any drug were used to generate clusters of symptoms suggestive of this syndrome. These clusters were then used as search terms to identify studies reporting the frequency of such neonatal outcomes (including single behavioral signs, poor neonatal adaptation, and admission to neonatal intensive care unit [NICU]). The reference lists of identified articles were examined carefully for additional pertinent publications.

For inclusion in the present review, meta-analyses, clinical trials, observational studies, case series and single case reports had to evaluate neonatal events consistent with the syndrome after exposure to any prescription drug. Studies addressing the neonatal effects of drugs used for recreational purposes during pregnancy were excluded. Articles evaluating only teratogenic effects, congenital malformations, miscarriage, stillbirth and abortion were also excluded. Abstracts presented at national and international meetings were not included.

Results

Drugs associated with neonatal symptoms, consistent with a drug withdrawal or a pharmacological residual effect consequent to pre-birth exposure, belong to several psychotropic drug groups and include opioids, antidepressants, antiepileptic drugs (AEDs) and antipsychotics. Notably, the lipophilic chemical nature of these drugs generally allows their placental disposition and/or excretion into breastmilk, in accordance with the pharmacokinetics of each drug, thus explaining the variability of perinatal exposure and neonatal effects among drugs. Table 1 summarizes the main clinical patterns of these neonatal syndromes. Each drug class has been then discussed in details in the following sections.

Opioids

Opioids represent the most investigated drug class for their involvement in the occurrence of neonatal neuro-behavioral syndromes. This is largely due to the illicit use of these drugs for recreational purposes since immemorial time. Contrarily to other drug classes, there is no discussion about the fact that the mechanism underlying these symptoms result from residual pharmacological activity instead of a withdrawal effect, since the entire available literature always describe the symptoms as a NAS (Jansson, 2009). However, we can not excluded that some early symptom can be attributed to a residual opioid activity (see for instance Khan et al, 1997). Opioid-associated NAS has been documented in western countries since 1875, with a first case published in US in 1892.[5] In the USA, it has been estimated that from 2000 to 2009 antepartum opioids use increased from 1.19 to 5.63 per 1,000 live births.[9] Over the same period, the incidence of NAS increased from 7 to 27 cases per 1,000 admissions to NICU,[10] and related hospitalization costs per infant with NAS increased from \$39,400 to \$53,400.[9] The reason accounting for this epidemic remains unclear, even though most evidence points to prescription opioids, and not to their illicit use. In Canada, from 1992 to 2011, the incidence of opioid-related NAS increased by 15 folds (from 0.28 to 4.29 per 1,000 live births), and from 2006 to 2011 NAS could be ascribed to prescription opioids in 67% of cases.[11] In USA, from 2008 to 2012 about one third of fertile women was prescribed an opioid. In Norway, 6% of pregnant women filled at least one opioid prescription between 2004 and 2006.[12] A study performed in Tennessee estimated that 63% of the cases of NAS occurred in women receiving prescription opioids.[13] A large observational study (n=290,605), performed on the Medicaid database, indicated that the absolute risk of NAS due to prescription opioids, in the absence of other risk factors (history of opioid misuse or dependence, alcohol or other drug misuses, exposure to other psychotropic medications late in the pregnancy and smoking), was low (5.9 per 1,000 deliveries).[14] However, the risk increased with long term use as compared with the short term (relative risk: 2.05; 95% confidence interval [CI] 1.81-2.33), as well as for late pregnancy as use compared with early use (relative risk: 1.24; 95%CI 1.12-1.38), independently of additional risk factors.[14] Overall, 50-80% of opioid-exposed infants required a

pharmacologic treatment for NAS management.[15, 16, 5] Preterm infants have been reported as being at lower risk of opioid withdrawal, with less severe and/or prolonged courses.[17, 18]

Besides analgesic use, opioids are mainly prescribed for maintenance purposes in addicted women during pregnancy. The mainstay of this treatment is represented by the tapering of methadone or buprenorphine.[19] Evidence in favor of the use of buprenorphine over methadone is growing due to more favorable neonatal brain growth patterns with buprenorphine.[19] Although evidence supporting teratogenic effects of opioids is scarce,[20-23] the long term use during pregnancy has been associated with brain development impairments.[24, 25] Furthermore, although the occurrence of NAS has been reported for both methadone and buprenorphine,[26-32] it has been observed that prenatally buprenorphine-exposed neonates required significantly less morphine for NAS management, required a significantly shorter duration of NAS treatment, and had a significantly shorter hospital stay as compared with prenatally methadone-exposed neonates.[15, 33] Higher neurobehavioral score and less severe NAS have been described also in newborns after in utero exposure to buprenorphine, as compared with those exposed to methadone.[34] The relationship between methadone or buprenorphine dose and NAS severity is currently controversial, with some studies indicating an association and some not.[35-41] Other prescription opioids that have been associated with withdrawal syndrome include morphine,[42] codeine,[43-47] tramadol,[48-52] propoxyphene,[53-56] fentanyl,[57, 42] and pentazocine.[58-60] Besides individual genetic factors,[61] the onset of withdrawal signs and the peak of symptom severity likely depend on opioid pharmacokinetics. For instance, prenatal exposure to morphine displays a shorter time-to-onset of newborn withdrawal (average 36 hours), as compared with methadone (average 60 hours).[62] NAS associated with buprenorphine generally starts after approximately 12-48 hours and peaks at approximately 72-96 hours.[63] For tramadol, the onset was described within 35-48 hours, with a peak in 3-7 days.[48-50] For codeine, initial symptoms appears even after 2 hours, with a peak within 24-48 hours.[43, 46] Fentanyl-associated NAS was described to develop within 24 hours with a peak in 72 hours,[57, 42] even when the drug was administered by transdermal devices.[57]

The mechanism of opioid induced NAS is complex and not fully understood. Opioids are small lipophilic molecules that can easily cross the placental barrier.[16] One of the most accepted theories suggests a pivotal role for a second messenger, cyclic adenosine monophosphate (cAMP), responsible for signal transduction in several cellular systems. The activation of opioid receptors strongly inhibits adenylyl-cyclase, thus preventing the synthesis of cAMP. After repeated opioid exposure, the cells attempt to compensate for the lack of cAMP by enhancing the expression of adenylyl-cyclase. When opioid intake is discontinued, the hyper-expressed adenylyl-cyclase is no longer inhibited, with consequent overproduction of cAMP. The latter leads to an excessive release of norepinephrine (NE), which then binds noradrenergic

receptors, causing overactivation of the autonomic nervous system that becomes responsible for the onset of signs and symptoms associated with the withdrawal syndrome.[64-67]

Opioid-related NAS can develop with a range of different symptoms that affect critical regulatory functions of post-natal adaptation, ranging from neurologic hyperexcitability (insomnia, irritability, hypertonia, hyperreflexia, tremors, and seizures), to gastrointestinal (GI) symptoms (vomiting, diarrhea, feeding disturbances), and sympathetic/parasympathetic dysregulation (sweating, hyperthermia, tachypnea, and congestion).[68, 69] Several scales and scores have been developed to assess NAS severity in opioid-exposed infants.[70] These are very heterogeneous and include, amongst the others: Neonatal Abstinence Syndrome Score, known also as Finnegan score, the most used in USA[71] in its modified versions (an example is displayed in table 2);[72] Narcotic Withdrawal Score (Lipsitz Score);[73] the Neonatal Narcotic Withdrawal Index;[74] Neonatal Narcotic Withdrawal Inventory;[75] MOTHER NAS Scale (a modified version of the Finnegan scale).[15] In newborns with NAS, these scores are estimated by caregivers every few hours. Based on their values, standard thresholds have been defined to establish the extent (e.g. dose) and duration (e.g. dose-titration scheduling for maintenance approaches) of pharmacological and non-pharmacological interventions.[9]

The management of opioid-induced NAS is also controversial. The most common approaches include non-pharmacological and pharmacological interventions.[64, 76] Among non-pharmacological interventions, the infant feeding methods are the most explored. In particular, the effect of feeding approach has been investigated in seven observational retrospective studies.[77-83] Although these studies are flawed by significant limitations and their results are not easily comparable,[70] their findings suggest that, in infants with NAS breastfeeding from mothers stable in methadone or buprenorphine maintenance (i.e. not using illicit opioids) is associated with an overall decrease in the need for pharmacological treatment (30% reduction), a decrease in NAS scores as well as a decreased duration of pharmacological therapy and hospitalization (3-19 days shorter).[70] Notably, methadone excreted in the maternal milk may theoretically provide an indirect maintenance treatment for babies with NAS. However, a study showed that methadone concentration in the blood of newborns breastfed by methadone-maintenance mothers is too low to explain a “pharmacological compensation” of the delivery-induced drug withdrawal.[84] Thus, in this setting, the beneficial impact of breastfeeding on NAS symptoms likely results from the positive comfort associated with maternal contact.[84] Other non-pharmacologic approaches, for which lesser evidence of benefit in NAS is available, include rooming-in, bed type, infant position and non-insertive acupuncture.[70]

The pharmacological management of opioid-induced NAS may include a reintroduction of the discontinued drug (or an alternative safer opioid) or the use of symptomatic treatments. Orally administered morphine (morphine chloride or even in the form of opium tincture, 0.3-1.0 mg/kg/day, administered every 3-4 hours, titrated to effect and reduced

every 24-48 hours), or methadone (titrated in the range of 0.3-1.0 mg/kg/day, administered every 4-12 hours and then weaned) are the most commonly used first-line medications, although there is no evidence on what drug is superior.[70, 85] Buprenorphine has been also investigated in recent studies, showing a decrease in treatment duration and reduced hospital stay as compared with methadone[86] or opium solution.[87] Second lines of treatment include phenobarbital, clonidine and clonazepam.[16, 88, 64, 89] Notably, randomized clinical trials (RCTs) investigating the above pharmacological approaches are small, employed different assessment tools and protocols to escalate and wean medications, and adjusted for different covariates, and therefore they are very difficult to compare. In RTCs, morphine was shown to be more beneficial than phenobarbitone (significantly shorter duration of treatment and reduced need for second line treatment and NICU admission),[90] but less effective than opium tincture (n=33, longer length of treatment and length of hospitalization).[91] In another RCT, conducted on 25 infants with NAS, buprenorphine displayed a reduced length of hospital stay as compared with neonatal opium solution.[92] Finally, the benefits of add-on therapies to first line opioids, with clonidine and phenobarbital, have been investigated, showing a decrease in the duration of first line therapy, with phenobarbital showing shorter duration of treatment when directly compared with clonidine.[93, 94, 89]

Antenatal methadone exposure has been reported also to be associated with transient prolongation of QT interval in newborns, usually within the first 2 days of life.[95] This effect may partly explain the high rate of infant sudden death syndrome in newborns from mothers on maintenance with methadone, although the pathophysiology of this adverse outcome is likely to be multifactorial in nature.[96] In particular, this adverse effect has been ascribed to a direct toxicity after placental transfer of methadone and not to a withdrawal syndrome.[95]

Antidepressants

It has been estimated that 13.5% of pregnant women present depressive disorders.[97] Depression may have a negative impact on pregnancy outcomes, including low birth weight and prematurity, irritation, agitation, lethargy, reduced attention, and relationship issues between mother and child, with consequent learning and behavioral problems during childhood.[98, 99] Therefore, treatment with antidepressants is usually recommended.[97] In Europe, 1-3% of pregnant women take antidepressants (mainly selective serotonin reuptake inhibitors [SSRI, including fluoxetine, paroxetine, sertraline, citalopram, escitalopram and fluvoxamine] and serotonin-norepinephrine reuptake inhibitors [SNRI, including venlafaxine and duloxetine] because of their effectiveness and safety), while in the USA the percentage is about 4-13%. Overall, 25% of women treated with antidepressants continues their treatment during pregnancy, and 0.5% of women starts a treatment during pregnancy.[100]

In 2004, the US Food and Drug Administration (FDA) issued a class labeling change for SSRI and SNRI antidepressants, introducing a warning about the association of third trimester exposure to antidepressants and signs and symptoms consistent with NAS.[99] About 20-77% of children exposed in utero to SSRIs has been estimated to develop symptoms of NAS,[98] with paroxetine and fluoxetine having the higher incidence as compared to other SSRIs.[101-104] The incidence of NAS in newborns exposed in utero to tricyclic antidepressants (TCA) is about 20-50%.[98, 105] NAS symptoms associated with SSRIs, SNRIs and TCAs are similar and include a variety of mild to moderate behavioral, autonomic and neurological signs such as irritability, persistent crying, chills, tremors, restlessness, feeding difficulties, jaundice, vomiting, hypotonia, hypertonia and sleep disorders. [98, 106-120] However, NAS may rarely occur also with severe symptoms requiring NICU management, such as respiratory distress syndrome and seizures.[108, 121, 122, 119, 123-125, 109, 110, 126, 127] Motor signs, respiratory, GI and metabolic dysfunctions, usually mild to moderate and self-limiting, occur in the majority of cases shortly after birth, within the first 24-72 hours, and generally disappear within few weeks. Residual pharmacological effects of antidepressants occur immediately after the birth, and symptoms may depend on the specific antidepressant. Following exposure to TCAs, anticholinergic symptoms, such as urinary retention and constipation can be observed.[98] For the SSRIs, symptoms are expected to be similar to those of a serotonergic syndrome in adults.[98]

Several studies have attempted an estimation of the risk of NAS in babies exposed in utero to antidepressants. Late SSRI exposure is estimated to carry an overall risk ratio of 3.0 (95%CI 2.0-4.4) for NAS as compared with non-exposed or earlier exposures.[97] Grigoriadis et al.[128] found a significant increase in the risk of NAS as a result of exposure to antidepressants during pregnancy (odds ratio [OR]: 5.7; 95%CI 3.25-7.90), and its signs such as respiratory distress (OR: 2.20; 95% CI 1.81-2.66) and tremors (OR: 7.89; 95%CI 3.33-18.73).[128] In a study conducted on 997 infants, whose mothers had used antidepressants during the latter part of pregnancy, excess neonatal problems were observed more frequently after the use of TCAs than SSRIs; in particular, an increased risk was detected for respiratory distress (TCAs OR: 2.20; 95%CI 1.44-3.35; SSRIs OR: 1.97; 95%CI 1.38-2.83), neonatal hypoglycemia (TCAs OR: 2.07; 95%CI 1.36-3.13; SSRIs OR: 1.35; 95%CI 0.90-2.03), and neonatal seizures (TCAs OR: 6.8; 95%CI 2.2-16.0; SSRIs OR: 3.6; 95%CI 1.0-9.3), but not for neonatal jaundice (TCAs OR: 1.37; 95%CI 0.88-2.12; SSRIs OR: 0.96; 95%CI 0.63-1.46), after exposure to TCAs as compared to SSRIs.[125] As far as SNRIs are concerned, late-pregnancy exposure to duloxetine can be associated with a poor risk of NAS, but the extent of this risk remains unclear.[129] Notably, the risk of NAS after exposure to venlafaxine seems to be comparable to the risk after exposure to SSRIs.[98]

Antidepressants are known to cross the placental barrier.[130-132] The mechanism of NAS associated with SSRIs is not fully understood and likely reflects a similar condition of withdrawal as observed in adults.[133] Some

authors have speculated about a temporary deficiency of synaptic serotonin occurring after an abrupt withdrawal of an SSRI.[134] Indeed, during treatment serotonin re-uptake is blocked and therefore synaptic serotonin levels remain elevated. This circumstance could induce a down-regulation of post-synaptic serotonin receptors (desensitization), which could remain in their relatively hypoactive condition for days to weeks.[134] At delivery, the blockade of serotonin re-uptake is abruptly interrupted and serotonin synaptic levels are expected to rapidly decrease. This “serotonin shortage” and receptor desensitization are thought to translate into a decrease of serotonin transmission, which can have significant consequences not only on the serotonin system but even on the dopaminergic, noradrenergic and cholinergic neurotransmissions, owing to the modulating control exerted by serotonin on these pathways in the central nervous system (CNS). The alterations resulting from this neurotransmitter interplay may explain the development of NAS symptoms.[135, 101, 136, 134] Withdrawal from TCAs has been brought back to a cholinergic and adrenergic theory.[105] The cholinergic theory is based on the fact that TCAs bind both peripheral and central muscarinic receptors, with blockade of cholinergic activity, and consequent up-regulation of muscarinic receptors (that is an explanation for tolerance to cholinergic adverse effects). When TCAs are discontinued, the upregulation of muscarinic receptors promotes a condition of "cholinergic overdrive" in some patients.[135] Notably, this mechanism has been described for paroxetine too, and this circumstance may provide an explanation for the higher frequency of the NAS associated with paroxetine as compared with other SSRIs.[97]

The adrenergic theory holds that treatment with TCAs causes inhibition of norepinephrine reuptake, with an increase in the synaptic concentration of this mediator. Initially, this condition leads to a decrease in norepinephrine turnover and in a lowering of norepinephrine release mediated by the overactivation of presynaptic α_2 -adrenoceptors. However, with the prolonged drug intake, a down-regulation of presynaptic α_2 -adrenoceptors occurs, leading to a further increase in the synaptic accumulation of norepinephrine. Following an abrupt discontinuation of TCA therapy, the synaptic levels of norepinephrine would be expected to decrease rapidly, however owing to the desensitization of presynaptic α_2 -adrenoceptors, a significant facilitation of norepinephrine release is maintained for a certain period, with a subsequent temporary persistence of the activity of noradrenergic neurotransmission.[135]

The diagnosis of antidepressant-associated NAS is complicated by the lack of standard diagnostic criteria, the difficulty of discriminating between NAS and residual pharmacological effects, the overlapping between the two clinical pictures, and the metabolic immaturity of newborns.[98, 135, 137, 129] For SSRIs/SNRIs, the main differences between NAS and residual pharmacological effects (usually consistent with a picture of serotonergic overstimulation) are likely in the time-to-event onset and the serum concentrations of the drug or serotonin metabolites (i.e. 5-hydroxyindoleacetic acid [5-HIAA]) in the umbilical cord. Indeed, in the case of residual serotonin toxicity, symptoms occur soon after the

delivery and high concentrations of antidepressants can be detected in the umbilical cord serum.[98] By contrast, NAS symptoms occur within 24-72 hours from labor,[118, 138, 139] and 5-HIAA levels are low and the concentration inversely related with symptoms severity.[140] The time-to-onset and duration of withdrawal symptoms or serotonergic overstimulation in exposed infants depend of the pharmacokinetics of the specific antidepressant.[106] The half-life of the antidepressant might influence the risk of NAS and serotonin toxicity, while the drug dose does not seem to be related with the occurrence or severity of NAS.[98]

Commonly used scores for evaluating the severity of NAS (i.e. Finnegan score)[72] have never been validated for this drug class. In most cases, symptoms are non-specific, and the diagnosis is carried out by excluding infectious problems, neurological diseases, intoxications and metabolic dysfunctions (hypoglycemia, hypocalcemia, etc.).[98, 141, 137] Maternal depression is an important confounding factor.[135] Oberlander et al.[142] showed that only the neonatal respiratory distress was a symptom related to antidepressant withdrawal, while other neonatal symptoms, such as feeding problems, jaundice and even convulsions, were found in both exposed and non-exposed infants from depressed mothers.[142] Moreover, pregnant women taking antidepressants are often exposed to other treatments with psychotropic drugs,[109] such as benzodiazepines (BZDs),[127] which might contribute to the occurrence of neonatal adverse effects.[103] Children undergoing a NAS typically display normal cognitive abilities, but they may have a higher risk of developing social and behavioral abnormalities than children without NAS. A follow-up of these infants has been recommended.[143]

Most NAS cases are mild in nature, being characterized by short duration and self-limiting symptoms, and, therefore they do not generally require a treatment.[144] The medical management consists mainly in a close monitoring of the newborn exposed to antidepressants in utero at least in the first hours after the delivery,[145] should the syndrome occur fully, a supportive care must be provided.[102, 146, 147, 97, 98, 137] The evolution of the clinical picture can be monitored using the Finnegan score: a score of 8 on a survey of more than 3 consecutive measurements is considered a serious NAS requiring medication or transfer to NICU.[137, 98, 141, 126] Phenobarbital has shown a good safety profile in newborns and it can be used to control irritability, stiffness and seizures.[141, 148, 108, 98, 137, 147] Breastfeeding has shown to reduce the severity and duration of NAS.[98, 145] Available evidence does not allow to exclude that in mothers receiving SSRIs during lactation this beneficial effect can be partly explained by the excretion of low amounts of these antidepressants into the maternal milk. In this way, drug exposure would not be abruptly interrupted by delivery. Therefore, some authors recommend breastfeeding as a preventive strategy for SSRI-induced NAS.[98, 149-151, 145] In this case, the differential diagnosis between SSRI/SNRI serotonin withdrawal and toxicity is a critical issue for the clinical management.[138, 4] Indeed, in case of withdrawal, the newborn may benefit from being treated with a SSRI through lactation; by contrast, in case of serotonin toxicity, being exposed to an SSRI may have detrimental effects.[4]

Antiepileptic drugs (AEDs)

AEDs include a variety of drugs that are highly heterogeneous both for mechanisms of action and indications. These drugs have been associated with the development of neonatal abnormalities related to drug exposure in utero, described as neonatal withdrawal symptoms or residual toxicities. In this section, neonatal syndromes related to maternal exposure to AEDs have been reviewed with a focus on barbiturates and BZDs, for which specific information are available in the medical literature.

Epilepsy has been estimated to affect 0.3-1% of pregnant women and its treatment with AEDs should be aimed at carefully balancing the risk of seizures for both the mother and the baby[152] with the risk of teratogenic and other adverse effects in the newborn.[153-158] In a recent study, performed on data from the Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) database, it was estimated that from 2001 to 2007 the use of AEDs during pregnancy increased, mainly owing to a 5-fold increase in the use of newer AEDs. Older AEDs (i.e. BZDs, valproic acid [VPA], carbamazepine and phenytoin) were the most commonly used drugs, with BZDs being involved in over half of the exposed pregnancies. Among the newer AEDs, the most frequently used drugs were: gabapentin; lamotrigine; topiramate; oxcarbazepine; levetiracetam. The most prevalent indications were psychiatric disorders, pain disorders and epilepsy.[159] Second-generation AEDs (e.g. lamotrigine) are progressively replacing first-generation AEDs (e.g. VPA) both in monotherapy and polytherapy in pregnancy.[160-162] The trend towards an increased use of the newest AEDs in pregnant women is in line with the clinician concerns about the teratogenic risk associated with older compounds, such as VPA, phenytoin, phenobarbital, primidone and carbamazepine. Newer AEDs appear to be safer in pregnancy as compared with older AEDs, even though data are still limited to issue solid recommendations.[163, 164, 159]

NAS has been described in newborns exposed prenatally to AEDs. Several small observational studies have attempted an estimation of the frequency of withdrawal syndrome in babies born from mothers exposed to AEDs during pregnancy. A frequent limitation of investigations attempting a comparison is the selection of non-epileptic mothers as reference group, which does not allow to exclude that epilepsy may have a role in the occurrence and severity of symptoms. A prospective study (n=123) estimated that the frequency of withdrawal-related jitteriness, in babies exposed in utero to phenytoin alone, VPA alone or a combination of other AEDs (VPA, carbamazepine, phenytoin, phenobarbital, sulthiame, and primidone), was 18% vs 0% in non-epileptic women.[165] Another study[166] evaluated the effects of in utero exposure to AEDs using apathy and hyperexcitability scores, and showed higher apathy scores for phenobarbital and phenytoin, and higher hyperexcitability scores for VPA, as compared with a non-epileptic reference group. Dean et al. (2002) observed that 50 (20%) of 255 newborns exposed in utero to AEDs experienced a withdrawal syndrome with

a relative risk of 7.45 (95%CI 1.06-52.37), when compared to 1 case (3%) over 38 non-exposed epileptic pregnancies.[155] Phenobarbital monotherapy was less likely to be associated with neonatal withdrawal symptoms (13%), while polytherapy was most likely to be (30%, $p=0.001$). Neonatal withdrawal was significantly more frequent in newborns exposed to VPA monotherapy (24%, $p=0.006$) and phenytoin monotherapy (21%, $p=0.018$) than in the non-exposed group (3%).[155] A small study described 10 cases of NAS among 22 newborns exposed in utero to VPA as monotherapy or combined with carbamazepine.[167] A case-control study described 4 cases of NAS among 37 newborns exposed to VPA monotherapy or in combination with primidone, carbamazepine or lamotrigine, as compared with no cases in control groups (untreated epileptic women or healthy women).[153]

Symptoms of AED-related NAS are similar to those of opioid withdrawal. They usually occur during the first few hours after birth, up to one week after delivery, and may persist for weeks and months.[168-171] Symptoms may include: irritability; jitteriness; abnormal tone; hypotonia; seizures; feeding disorders; hypoglycaemia; apnoeic episodes and vomiting.[152, 166, 155, 172, 173] Hypotonia and feeding problems may depend on the sedative effect of AEDs.[169] Notably, withdrawal symptoms have been described as a part of the “fetal anticonvulsant syndrome”, characterized also by malformations, developmental disorders and facial dysmorphism.[172] VPA in monotherapy or polytherapy (in combination with phenytoin, carbamazepine, ethosuximide, or primidone), oxcarbazepine and lamotrigine, used during pregnancy for the treatment of epilepsy, have been described in case reports as the suspected causative drugs for NAS.[152, 174, 169, 175] Withdrawal symptoms were reported also in infants born from women treated during pregnancy with gabapentin or baclofen for the management of neuropathic pain and paraplegia, respectively.[176, 171, 170] In late preterm infants, withdrawal symptoms developed 1-3 days after birth and were preceded by bradycardia, difficulty in breathing, cyanosis, intercostal retractions, apnea, and hypotonia at birth.[152, 174, 176]

Most AEDs cross the placenta by diffusion in substantial amounts.[166] For VPA and gabapentin an active transportation has been also described.[177, 168, 178-180] Notably, for many new generation AEDs, gestational pharmacokinetic data are still limited.[177] The occurrence of withdrawal symptoms in newborns from epileptic mothers has been correlated positively with the mean dose of VPA given in the third trimester and the concentration of the free fraction of VPA in maternal plasma at the delivery.[167, 169] VPA concentrations at birth have been correlated with hyperexcitability in the newborn, while apathy was associated with high serum concentrations of unbound phenobarbital.[166] Jitteriness was related to phenytoin concentrations in maternal blood and cord blood.[165] Of note, these data are not conclusive, since other studies failed to show any correlation between the drug dose or cord blood serum concentrations and the occurrence of withdrawal syndrome.[155, 165] Furthermore, deficient hepatic and renal elimination capacities in the neonate can result in a longer half-life of AEDs when compared to adults, such as in the case

of VPA. By contrast, in utero exposures to phenytoin, carbamazepine and primidone have shown to induce the fetal hepatic enzyme systems, resulting in drug elimination patterns similar to adults.[168] The presentation of signs and symptoms of NAS may sometimes be delayed, consistently with the elimination time of drug metabolites in the neonate. Alternatively, the delay can be explained by an increase in AED concentrations after the delivery, likely due to their slow disposition from the CNS and lipid stores.[171, 174] Indeed, the fetus can be considered as a 'deep compartment' filled up by these compounds during long-term therapy throughout pregnancy.[168] Accordingly, after delivery, AEDs (phenobarbital, primidone, VPA and BZDs) have been found to persist in neonatal plasma for several days. This mechanism can explain some earlier neonatal events (direct toxicity) such as sedation, hypotonia, weak sucking, feeding problems and later neonatal withdrawal syndrome.[169, 173, 181] Signs of drug withdrawal in neonates can be monitored using the Finnegan scoring system.[176, 170, 174] Other scores have been used occasionally.[166]

The mechanism underlying AED-induced NAS has not been fully understood yet, and it is likely to differ across the various drugs. In adults, the γ -aminobutyric acid (GABA) system is known to play a pivotal role in the pathogenesis of withdrawal symptoms associated with BZDs, barbiturates, gabapentin and baclofen.[182, 183] Prolonged use of baclofen induces also the inhibition of monoamine neurotransmitter systems leading to the upregulation of dopamine and noradrenergic receptors. When baclofen is suddenly withdrawn, a disinhibition of the previously suppressed monoamine pathways occurs, with a consequent release of norepinephrine and dopamine onto upregulated receptors, leading to autonomic arousal (i.e., tachycardia, hypertension, agitation, restlessness) as well as delusions, hallucinations, and delirium.[183] The administration of VPA in rats was related to increased levels of striatal met-enkephalin that might participate in the occurrence of VPA-induced abstinence behaviour.[184] Withdrawal symptoms observed with carbamazepine have been suggested to be consistent with those of TCAs, likely due to chemical similarities.[185] Hypoglycaemia belongs also to the symptoms expected for the AED withdrawal syndrome. This condition is often associated with neonatal feeding issues. However, hypoglycaemia may depend on a residual toxicity of in utero exposure to VPA, since this drug has been shown to decrease gluconeogenesis and impair glycogenolysis in newborns.[167, 152]

A standard treatment of AED-induced NAS has not been defined. Symptoms can be mild and transient or severe to such an extent to require transfer to NICU.[176, 152, 174, 169] Infants developing symptoms of withdrawal, after abrupt discontinuation of AEDs (VPA in mono- and poly-therapy), have been treated with phenobarbital and diazepam (in case of repeated seizures),[169, 167] or with the re-administration of the drug responsible for withdrawal (gabapentin, baclofen).[176, 170, 171] Some infants required enteral feeding or breast milk supplemented with formula milk, usually because of feeding problems caused by withdrawal symptoms.[167, 176] Among the preventive strategies, discontinuing AEDs during pregnancy is not usually an option, since a recurrence of seizures in pregnant women is expected.[155]

Monotherapy and the lowest drug dose may limit the risk of neonatal withdrawal.[169] Tapering down slowly the dose of AEDs (i.e. gabapentin) prior to delivery over a period of weeks to months can be useful in the minimization of NAS.[176, 172]

Barbiturates

Barbiturates have been indicated since decades for the treatment of several clinical conditions during pregnancy that, at least initially, included anxiety, sedation, prevention of hyperbilirubinemia in the newborn, preeclampsia and epilepsy.[186, 187] The management of epilepsy with barbiturates during pregnancy remains a controversial issue, since in utero exposure to these drugs may result in newborn behavioral abnormalities, neurological impairments and/or NAS.[187, 188]

Although the abstinence syndrome is well described in adults,[189] barbiturate-related NAS is less documented, and it is often described by case reports and small case series published during the 70s, when these compounds were more frequently prescribed by physicians for the management of epilepsy in pregnant women as well as for preeclampsia.[190, 191, 187, 166, 188] These early cases provide limited information, mainly due to diagnostic uncertainties related to the great variability of symptoms and to the pioneering approach to NAS. In a retrospective study, performed in 15 infants born from mothers receiving barbiturates during pregnancy, Desmond et al.[187] reported that the syndrome develops with an early acute phase, characterized by symptoms such as persistent crying, tremors, sleeplessness, hiccups and mouthing, followed by a subacute phase, with symptoms like hyperphagia, episodes of prolonged crying, irritability, hyperacusia and sweating.[187] Other symptoms reported in literature include hypotonia, feeding accompanied by gagging, vomiting, jitteriness, and seizures.[191, 190, 192]

Although symptoms are similar to those observed in opioid-exposed infants, barbiturate withdrawal symptoms appear to have a later onset (median age: 6 days, range 30 minutes-14 days) than opioid ones (median age: 6 hours, range 10 minutes-2 days).[193, 187, 191] This delay can be explained by the mechanism of tissue accumulation (described above in the section dedicated to AEDs in general) and by the poor conjugating capacity of the neonate, as well as the poor glomerular and tubular function of immature kidneys.[187, 186, 188] The duration of symptoms can vary from 2 to 4 months (with a median of 3 months), although they may persist for up to 6 months.[187] Moreover, newborns receiving barbiturate (as compared with opiates) are less frequently jaundiced, have better Apgar scores, and have no apparent residual injury following withdrawal[191, 187] as well as no autonomic and GI distress.[190]

Barbiturates can easily cross the placental barrier and can be detected at high concentrations in the newborn serum and umbilical cord serum.[193, 188, 194, 195] A lower plasma protein binding (3-43%) in newborns, as compared to adults (51%), could also explain the higher blood levels as compared with the mother.[196] Factors that may affect serum levels of phenobarbital in the offspring include maternal dose, gestational age, neonatal weight and days of life as well as the duration of prenatal exposure.[191, 188] The mechanism of barbiturates-induced NAS is not clear, but it is likely similar to that described in the section of this review dedicated to BZDs, thus involving GABA neurotransmission.[197]

Standard treatments for the management of barbiturate-associated NAS are not available. Phenobarbital has been shown to be effective in the management of the syndrome, even if an elevated rate of tolerance was reported. A daily dosage of 5-7 mg/kg/day of phenobarbital in newborns affected by seizures or drug abstinence syndrome has been considered useful and safe for infants.[196] As far as preventive approaches are concerned, evidence and data obtained from studies conducted on infants from pregnant epileptic women confirmed the need for treating them with the minimum effective dose, in order to reduce the risk of withdrawal in infants, following placental disposition.[188]

Benzodiazepines

BZDs are frequently used by women of reproductive age and by pregnant women for a variety of indications, including anxiety, sleep disturbances, control of seizures and managing of pre-eclampsia or eclampsia in the late phase of pregnancy.[198-200] It has been estimated that approximately 2-3% of pregnant women use BZDs.[201, 98, 202, 203]

Despite the relatively frequent use of BZDs during pregnancy, data on neonatal outcomes are still limited and the safety of these drugs in pregnancy, including their teratogenic potential, remains controversial.[204, 205, 201, 206-208] When BZDs are administered late in pregnancy, they are easily disposed into the fetus, where they have the potential to accumulate causing two major neonatal syndromes: a NAS designated as 'Opiate-like withdrawal syndrome' lasting several days and a 'Floppy infant syndrome' (FIS), characterized by signs of poisoning within the first hours or days.[209, 204] At present, the actual prevalence of neonatal issues with BZDs remains unknown, since they can be used also as illicit drugs. Moreover, a small number of studies have examined newborns exposed prenatally to BZD monotherapy, and the pathophysiology of neonatal syndromes associated with BZDs has been poorly described and understood.[5] [206] The neonatal consequences of BZD use at the end of pregnancy have been evaluated in an observational study performed by the Regional Pharmacovigilance Center of Tours (France) on 73 pregnancies recorded from 1998 to 2002.[210] The most commonly used BZDs were oxazepam, bromazepam, alprazolam, clonazepam and clorazepate. The indications included depression, anxiety, epilepsy, insomnia and psychiatric disorders. In this study, exposure to BZDs was associated

with adverse reactions in 51.5% of newborns, comprising an “impregnation syndrome” (characterized by hypotonia and hypoventilation) in 42%, and a withdrawal syndrome in 20% of the cases (tremors as the main symptom).[210] Another study, performed to investigate infant and maternal characteristics of NAS in selected Hospitals in Florida from 2010 to 2011, showed that BZDs were the second most commonly reported drug class associated with NAS (40.5%).[211] Lastly, an analysis of the Swedish Medical Birth Register found that a late exposure to BZDs and receptor agonists (zopiclone, zolpidem, zaleplon) is associated with a higher risk of respiratory problems (OR: 2.21; 95%CI 1.62-3.02) and low Apgar score (OR: 2.20; 95%CI 1.11-4.39). A trend towards an increased risk for signs of CNS disorders (e.g. seizures) was also detected, but it was not statistically significant (OR:1.53; 95%CI 0.42-3.92).[204] Notably, some case series and studies, conducted on specific BZDs (diazepam, clonazepam, lorazepam, oxazepam, chlordiazepoxide, midazolam), did not show any neonatal toxicity or withdrawal syndromes in babies born from mothers who had taken BZDs during pregnancy.[212-219]

Symptoms of NAS and FIS are largely similar and it can be difficult to distinguish them, since the two syndromes may occur in sequence and their symptoms can partly overlap.[98, 202] Signs and symptoms of these syndromes have been described in several case reports and case series of pregnant women exposed to BZDs.[220-226, 216, 227, 209, 228-235, 214, 236-240, 200] Symptoms of both NAS and FIS are documented also in dated observational studies.[241-247]

NAS can be hardly recognized since it may start several days after delivery, up to 21 days in the case of chlordiazepoxide,[233] and symptoms may last for up to 3-6 months.[207, 248] Time-to-onset and duration of symptoms correlates well with the pharmacokinetics and placental disposition of BZDs, and their accumulation in neonatal tissues.[200] NAS symptoms reported in case reports include: tremors; irritability; hyperactivity; hypertonicity; tachypnea; vigorous sucking; poor weight gain; loose stools; vomiting.[220, 222, 225, 227, 230-233, 237, 200] The involved BZDs included diazepam (10-20 mg/day), chlordiazepoxide (20-30 mg/day), lorazepam (1 mg/day), alprazolam (1.5-8 mg/day), oxazepam and clobazam taken for the management of psychiatric disorders and anxiety throughout pregnancy or in the last 3-5 months.[220, 222, 225, 227, 230-233, 237, 200] Concomitant medications may have contributed to the occurrence of symptoms.[222, 227] Notably, in one case the infant died at 6 weeks of age, following a withdrawal syndrome associated with in utero exposure to diazepam treated with phenobarbital for 28 days. Death was attributed to the sudden infant death syndrome.[227]

Usually, FIS occurs when the fetus is exposed to long-acting BZDs on long-term basis, or when BZDs are administered shortly before the delivery, leading to a newborn intoxication of variable severity and duration. FIS symptoms (hypotonia, inactivity, weak cry, lethargy, sucking difficulties, low Apgar score, hypothermia, apnea, cyanosis, hyperbilirubinemia, CNS depression) occurred mainly within the first hours after labor and lasted for up to 14 days.[223,

224, 226, 216, 209, 228, 229, 234, 235, 214, 221, 236, 240] Diazepam (10-30 mg i.v. or 6-25 mg/day) was the mostly reported drug, followed by nitrazepam (5-10 mg/day), lorazepam (7.5 mg/day), chlordiazepoxide (500 mg i.v. or 100 mg/day), clonazepam (0.75 mg/day) and flunitrazepam, taken late in pregnancy for treatment of psychiatric disorders, or during labor in the case of pre-eclampsia or premature labor.[223, 224, 226, 216, 209, 228, 235, 214, 221, 240] Only few reports have described cases of neonatal apnea or mild depression associated with maternal exposure to clonazepam (5.5 mg/day) for treatment of epilepsy.[229, 236] In some reports, we cannot exclude the contribution of other psychotropic medications to the occurrence of neonatal symptoms.[209, 224, 226, 216, 228, 214]

The onset of NAS and FIS, their severity, and duration can be influenced by a number of factors: properties of the specific drug (plasma protein binding, ionization, lipophilicity, molecular weight, half-life, oral bioavailability), maternal treatment (dose, duration of exposure, time of last dose intake, co-medication with other drugs), infant characteristics (fetal absorption and storage, postnatal tissue binding and release, metabolism and excretion), and underlying maternal/fetal conditions.[204, 98, 227] Neonatal complications following in utero exposure to BZDs seem to be related also to the lipophilic nature of these drugs that allows an easy crossing of the placental barrier.[249, 204, 225, 235, 245, 223] Placenta can be considered also as a 'deep compartment' where the drug and its metabolites accumulate and are eliminated slowly, in a similar situation to that described generally for AEDs in the previous section.[225] Oxazepam, lorazepam, nitrazepam and, especially, flunitrazepam, appear to penetrate the human placenta more slowly than diazepam, but the clinical significance of this remains undetermined.[249, 212, 213] Long-acting BZDs (i.e. diazepam, chlordiazepoxide, chlorazepate, flurazepam, prazepam, nitrazepam) have sustained actions, that often can produce a 'hangover' type of effect with long-term treatments resulting in drug accumulation. Short-acting drugs (i.e. alprazolam, lorazepam, oxazepam, temazepam, lormetazepam) display a relatively little residual effect, but they can induce withdrawal symptoms more commonly.[200] Due to immaturity, less total body fat, and differences in the overall drug exposure, preterm infants may exhibit fewer signs of withdrawal than term infants. However, it is conceivable that the drug metabolism can be delayed in the premature neonate with reduced enzymatic functions in the liver.[213, 247] The long half-life of some BZDs and the immaturity of metabolic pathways in the newborn are not the only factors to be considered for explaining the persistence of neonatal symptoms for weeks after birth. Indeed, BZDs can be relatively easily metabolized by the neonate, and some BZDs (i.e. diazepam and clorazepate) can be converted into active compounds with a longer half-life than those produced by the maternal metabolism.[209, 213, 247, 227]

Infants may develop NAS with the classical mechanism of abrupt BZD discontinuation after a passive addiction acquired during pregnancy.[250] The underlying mechanism seems to be related to the mechanism of action of these drugs, and it likely results from the modulation of GABA-A receptors. Indeed, BZDs enhance the affinity of GABA-A

receptor for GABA, and this results in an increment of chloride conductance, thus promoting a condition of CNS depression.[251, 202]

The mechanism and significance of seizures associated with BZD withdrawal are unclear.[16] In adults, chronic therapy with BZDs may lead to conformational changes in GABA-A receptors, with a decrease in receptor affinity resulting in a decreased GABA activity. When BZDs are withdrawn, the condition of decreased GABA receptor activity leads to a reduced GABA inhibitory control on excitatory neurotransmitters, thus promoting a pro-excitatory status in the CNS.[252] BZDs with a short half-life, such as oxazepam and temazepam, do not usually result in toxicity, but the risk of withdrawal is increased as compared to BZDs with a longer half-life.[98] The mechanism by which BZDs can induce FIS is likely related to an enhancement of GABA effects on GABA-A receptors at limbic, thalamic, and hypothalamic levels, resulting in sedative, hypnotic, anxiolytic, anticonvulsant, and muscle relaxant effects.[199] The fetal BZD effects seem to be mediated by a central depression of cardiac and/or respiratory reflex centers.[253] High medication dosages (i.e. diazepam > 30 mg)[245] and BZDs with a long half-life (i.e. nitrazepam and diazepam) were shown to have the highest risk owing to their accumulation in newborns.[98]

The standard management of BZD-related neonatal syndromes (NAS and FIS) has not yet been defined, as well as a treatment protocol driven by an assessment tool.[5] The Finnegan score, to assess the severity of withdrawal syndrome, can be useful for initiating, monitoring, and terminating treatments in neonates,[225, 202, 246] as well as the Apgar score to evaluate acute neonatal outcomes.[246, 254] The initial treatment option is commonly based on a supportive non-pharmacological intervention, and symptoms resolve spontaneously without sequelae.[224, 221, 199] Mechanical feeding and ventilation have been described for the management of the most severe acute phases.[228] In the most severe situations, a pharmacological treatment can be required.[202] There is general agreement that neonates can benefit from sedative pharmacotherapy.[5] Three cases of severe tremors, occurred in the newborns after diazepam exposure in utero, were treated with phenobarbital.[227] Two case reports showed rapid, complete and sustained reversal of prolonged apnea and hypotonia induced by diazepam following treatment with flumazenil.[223, 209]

Current information is not sufficient to determine whether the potential benefits of BZD treatment in pregnant women overcome the risk for the fetus.[199] Bearing in mind the relative risk of drug exposure versus the potential impact of untreated psychiatric disorders,[214] when necessary, physicians should prescribe BZDs that have more robust safety data, in monotherapy, at the lowest effective dose for the shortest period of time, dividing the daily dosage into at least two doses and avoiding high single doses, multidrug regimes, and repeated and prolonged administration of BZD during pregnancy.[234, 199] If possible, the use of the shorter acting agents should be considered and their discontinuation should be performed with doses well tapered down prior to delivery.[200, 199]

Antipsychotics

The prevalence of pregnancy in women with schizophrenic and other severe and persistent psychiatric disorders (SPPDs) has increased since the deinstitutionalization of mental hospitals and the consequent increased availability of sexual partners.[255-257] Moreover, the progressive reduction of use of first generation antipsychotics (FGAs), endowed with hyperprolactinemic effects that may exert a control on fertility, in favor of second generation antipsychotics (SGAs), often lacking effects on fertility, are further fostering the frequency of pregnancy in patients with SPPD.[258, 259]

Evidence regarding the impact of pregnancy on the course of schizophrenia is inconclusive. Women with a history of psychotic disorders may experience a worsening rather than an improvement of symptoms during pregnancy. [260, 261] As far as the bipolar disorder is concerned, the issue of whether this disease worsens during pregnancy is controversial, with some studies showing a worsening[262, 263] and other studies showing no consequences.[264-268] In this scenario, it is particularly important that the mental health of women with SPPDs is stable if they are about to become parents.

Antipsychotics are effective medications for psychotic and bipolar manic episodes, and their use is rising among pregnant women with bipolar disorder, schizophrenia, and unipolar depression as well as other SPPDs.[269-272] However, reproductive safety data on these drugs are limited. Studies investigating the teratogenic potential of antipsychotic medications have shown a general increase in the risk of malformations associated with the overall drug class. This finding does not allow to exclude that the underlying disease or unidentified confounding factors may explain the increased risk.[273] Overall, the use of both SGAs and FGAs during late pregnancy has been associated with increased rates of neonatal complications (i.e. deficits in neuromotor performance, hypertonicity, tremors) as compared with exposure to antidepressant and non-psychotropic drugs.[274, 275]

In 2011, the US FDA issued a warning about neonatal extrapyramidal symptoms and possible medication withdrawal based on data from the Adverse Event Reporting System (AERS).[276] Indeed, from 2008 to 2011 the AERS database identified 69 cases of neonatal extrapyramidal or withdrawal symptoms associated with several antipsychotic drugs. The reported symptoms included agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder. Blood levels were not provided, making it not possible to determine whether the events resulted from NAS or residual pharmacological effects. The time to event onset ranged from delivery to one month after delivery. Symptoms varied in severity: some neonates recovered within few hours or days without specific treatment, while others required NICU support and prolonged hospitalization.[276]

A study on 142 live births, recorded by the Australian National Register of Antipsychotic Medication in Pregnancy (NRAMP), described medication withdrawal symptoms in 15% of babies. These newborns have displayed at least two of the following symptoms: excessive high pitched crying, pronounced Moro reflex, myoclonic jerks, intermittent bouts of sneezing and/or yawning, excessive drowsiness, tremors, pronounced irritability, difficult feeding, vomiting and loose stools.[277] Babies who experienced withdrawal symptoms had been exposed to higher doses of antipsychotics at 12 weeks of gestation (4.4 mg/ day vs 2.7 mg/day), though this difference did not reach statistical significance ($p=0.162$). Symptoms were prolonged in several babies, lasting up to 6–8 weeks.[277]

Differences can be highlighted among individual antipsychotic drugs. Neonatal complications ranging from mild withdrawal reactions to seizures have been described for risperidone. [278-281] A case report described a case of hyperbilirubinemia, thermoregulation and feeding problems associated with in utero exposure to risperidone (4 mg/day), requiring hospitalization of the newborn for 6 weeks.[280] Neonatal alterations associated with late in utero exposure to haloperidol may include thermoregulation impairments, decreased muscle tone, tremor on stimulation, vomiting, and poor feeding.[282] In a study, neonatal symptoms were observed in 8 out of 30 (27%) olanzapine-exposed infants versus one out of 51 (2%) non-exposed controls. These symptoms included respiratory distress (2 cases), hypotonia (1 case), poor sucking or feeding difficulty (2 cases), and unspecified withdrawal syndrome (3 cases).[283] For clozapine, reported neonatal complications include retinopathy, transient and severe neonatal hypoxemic encephalopathy and FIS.[284-287, 273, 288, 289, 224, 290-292] Two case reports have described delayed extrapyramidal symptoms in infants following prenatal fluphenazine administration. [293, 294] One developed neurologic symptoms, such as choreoathetoid and dystonic movements of the upper limbs, jitteriness, and hypertonicity that began 3 weeks after birth and lasted for 9 months. The second case had extrapyramidal manifestations that began 4 weeks after delivery. Both infants responded to treatment with diphenhydramine hydrochloride. In these two cases, respiratory effects were not reported. Another case described an infant with severe rhinorrhea and upper respiratory distress after 8 hours from birth.[295] Over the next 48 hours nasal congestion, rhinorrhea, extrapyramidal movements and vomiting improved and the baby was discharged on day 3. Nasal congestion and rhinorrhea persisted for 3 months.

All psychotropic medications can diffuse readily to the fetus across the placenta, due to their relatively small molecular size and lipophilic properties.[296] Fetal exposure to these drugs appears to vary according to the level of placental transfer. To quantify the placental permeability to antipsychotic medications, Newport et al. (2007)[297] conducted a prospective observational study in which maternal and umbilical cord plasma samples were collected at the delivery from 50 women exposed to antipsychotics in pregnancy. The highest placental transfer ratio was observed for olanzapine (mean ratio \pm standard deviation: $72.1 \pm 42.0\%$), followed by haloperidol ($65.5 \pm 40.3\%$), risperidone ($49.2 \pm$

33.9%) and quetiapine ($23.8 \pm 11.0\%$). The mechanism underlying these effects is unclear. Withdrawal symptoms have been suggested to depend on a cholinergic rebound, rather than a dopaminergic-blockade.[298, 299] However, we cannot rule out that at least a part of early symptoms is related to a residual toxicity.

A standard treatment of neonatal complications associated with in utero exposure to antipsychotic medications is not available. In an analysis of 114 babies in the NRAMP database, those who were exclusively breastfed early after delivery were less likely to experience withdrawal symptoms than those receiving exclusively artificial feeding (9 of 74 [12.2%] vs 11 of 40 [27.5%]; OR: 2.74, 95% CI 1.02-7.32).[300] Mild symptoms may resolve spontaneously without treatments. The clinical management of the most severe cases is based on symptom control with sedative drugs, such as phenobarbital and BZDs.[276]

Other drugs

In the medical literature, NAS or residual pharmacological effects due to drug exposure during pregnancy have been anecdotally described for clonidine (hypertension related symptoms),^[301] hydroxyzine (neurological symptoms),^[302, 303] methyl dopa (neonatal jitteriness),^[304] pyridoxine (neonatal seizures),^[305] and lithium (FIS).^[98] However, the evidence for these drugs is very limited and further studies are needed.

Conclusions

Several drugs prescribed during pregnancy can be associated with the development of neonatal abnormalities, resulting from delivery-related withdrawal symptoms or representing a direct harm of the drugs accumulated in the blood and tissues of the newborn during the fetal period. These drugs are substantially used to treat CNS diseases or are able to interfere with neurotransmission both in the brain or in the peripheral nervous system. These effects can be severe and rarely fatal, and their early recognition and management can be helpful in reducing their clinical impact on newborns. Unfortunately, with the potential exception of opioids, validated protocols for the assessment and management of withdrawal or residual toxic effects of these drugs in neonates are often lacking and incomplete. Spontaneous reporting of these adverse reactions seems limited, although it might represent a useful tool for improving our knowledge about drug-induced neonatal syndromes.

References

1. Friedman JM. ABCDXXX: The obscenity of postmarketing surveillance for teratogenic effects. *Birth defects research Part A, Clinical and molecular teratology*. 2012;94(8):670-6. doi:10.1002/bdra.23043.
2. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. *Lancet (London, England)*. 2000;356(9237):1255-9. doi:10.1016/s0140-6736(00)02799-9.
3. Fabiano V, Mameli C, Zuccotti GV. Adverse drug reactions in newborns, infants and toddlers: pediatric pharmacovigilance between present and future. *Expert opinion on drug safety*. 2012;11(1):95-105. doi:10.1517/14740338.2011.584531.
4. Koren G. A new indication for therapeutic drug monitoring in the neonate. *Therapeutic drug monitoring*. 2006;28(1):1.
5. Jones HE, Fielder A. Neonatal abstinence syndrome: Historical perspective, current focus, future directions. *Preventive medicine*. 2015;80:12-7. doi:10.1016/j.ypmed.2015.07.017.
6. Allegaert K, van den Anker JN. Neonatal withdrawal syndrome: reaching epidemic proportions across the globe. *Archives of disease in childhood Fetal and neonatal edition*. 2016;101(1):2-3. doi:10.1136/archdischild-2015-309566.
7. Koren G, Finkelstein Y, Matsui D, Berkovich M. Diagnosis and management of poor neonatal adaptation syndrome in newborns exposed in utero to selective serotonin/norepinephrine reuptake inhibitors. *Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC*. 2009;31(4):348-50.
8. Jordan AE, Jackson GL, Deardorff D, Shivakumar G, McIntire DD, Dashe JS. Serotonin reuptake inhibitor use in pregnancy and the neonatal behavioral syndrome. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2008;21(10):745-51. doi:10.1080/14767050802255488.
9. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. *Jama*. 2012;307(18):1934-40. doi:10.1001/jama.2012.3951.
10. Tolia VN, Patrick SW, Bennett MM, Murthy K, Sousa J, Smith PB et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. *The New England journal of medicine*. 2015;372(22):2118-26. doi:10.1056/NEJMsa1500439.
11. Turner SD, Gomes T, Camacho X, Yao Z, Guttman A, Mamdani MM et al. Neonatal opioid withdrawal and antenatal opioid prescribing. *CMAJ open*. 2015;3(1):E55-61. doi:10.9778/cmajo.20140065.
12. Engeland A, Bramness JG, Daltveit AK, Ronning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-2006. *British journal of clinical pharmacology*. 2008;65(5):653-60. doi:10.1111/j.1365-2125.2008.03102.x.
13. Warren MD, Miller AM, Traylor J, Bauer A, Patrick SW. Implementation of a statewide surveillance system for neonatal abstinence syndrome - Tennessee, 2013. *MMWR Morbidity and mortality weekly report*. 2015;64(5):125-8.
14. Desai RJ, Huybrechts KF, Hernandez-Diaz S, Mogun H, Paterno E, Kaltenbach K et al. Exposure to prescription opioid analgesics in utero and risk of neonatal abstinence syndrome: population based cohort study. *BMJ (Clinical research ed)*. 2015;350:h2102. doi:10.1136/bmj.h2102.
15. Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. *The New England journal of medicine*. 2010;363(24):2320-31. doi:10.1056/NEJMoa1005359.
16. Hudak ML, Tan RC. Neonatal drug withdrawal. *Pediatrics*. 2012;129(2):e540-60. doi:10.1542/peds.2011-3212.
17. Doberczak TM, Kandall SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. *The Journal of pediatrics*. 1991;118(6):933-7.
18. Liu AJ, Jones MP, Murray H, Cook CM, Nanan R. Perinatal risk factors for the neonatal abstinence syndrome in infants born to women on methadone maintenance therapy. *The Australian & New Zealand journal of obstetrics & gynaecology*. 2010;50(3):253-8. doi:10.1111/j.1479-828X.2010.01168.x.

19. Welle-Strand GK, Skurtveit S, Tanum L, Waal H, Bakstad B, Bjarko L et al. Tapering from Methadone or Buprenorphine during Pregnancy: Maternal and Neonatal Outcomes in Norway 1996-2009. *European addiction research*. 2015;21(5):253-61. doi:10.1159/000381670.
20. Yazdy MM, Mitchell AA, Tinker SC, Parker SE, Werler MM. Periconceptional use of opioids and the risk of neural tube defects. *Obstetrics and gynecology*. 2013;122(4):838-44. doi:10.1097/AOG.0b013e3182a6643c.
21. Nasiraei-Moghadam S, Sahraei H, Bahadoran H, Sadooghi M, Salimi SH, Kaka GR et al. Effects of maternal oral morphine consumption on neural tube development in Wistar rats. *Brain research Developmental brain research*. 2005;159(1):12-7. doi:10.1016/j.devbrainres.2005.06.012.
22. Broussard CS, Rasmussen SA, Reefhuis J, Friedman JM, Jann MW, Riehle-Colarusso T et al. Maternal treatment with opioid analgesics and risk for birth defects. *American journal of obstetrics and gynecology*. 2011;204(4):314.e1-11. doi:10.1016/j.ajog.2010.12.039.
23. Kivisto K, Tupola S, Kivitie-Kallio S. Prenatally buprenorphine-exposed children: health to 3 years of age. *European journal of pediatrics*. 2015;174(11):1525-33. doi:10.1007/s00431-015-2562-0.
24. Fodor A, Timar J, Zelena D. Behavioral effects of perinatal opioid exposure. *Life sciences*. 2014;104(1-2):1-8. doi:10.1016/j.lfs.2014.04.006.
25. Yuan Q, Rubic M, Seah J, Rae C, Wright IM, Kaltenbach K et al. Do maternal opioids reduce neonatal regional brain volumes? A pilot study. *Journal of perinatology : official journal of the California Perinatal Association*. 2014;34(12):909-13. doi:10.1038/jp.2014.111.
26. Baglin S, Avenel S, Renaud C, Bavoux F, Francoual C, Badoual J. [Withdrawal syndrome in a newborn infant born to an addicted mother receiving methadone]. *Archives de pediatrie : organe officiel de la Societe francaise de pediatrie*. 1995;2(7):702-3.
27. Dahan S, Elefant E, Girard I, Azcona B, Champion V, Mitanchez D. [Neonatal seizures, buprenorphine abstinence syndrome, and substitutive treatment with morphine]. *Archives de pediatrie : organe officiel de la Societe francaise de pediatrie*. 2011;18(3):287-90. doi:10.1016/j.arcped.2010.12.003.
28. Hagopian GS, Wolfe HM, Sokol RJ, Ager JW, Wardell JN, Cepeda EE. Neonatal outcome following methadone exposure in utero. *The Journal of maternal-fetal medicine*. 1996;5(6):348-54. doi:10.1002/(sici)1520-6661(199611/12)5:6<348::aid-mfm11>3.0.co;2-d.
29. Herve F, Quenum S. [Buprenorphine (Subutex) and neonatal withdrawal syndrome]. *Archives de pediatrie : organe officiel de la Societe francaise de pediatrie*. 1998;5(2):206-7.
30. Lacroix I, Berrebi A, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine in pregnant opioid-dependent women: first results of a prospective study. *Addiction (Abingdon, England)*. 2004;99(2):209-14.
31. Liu WF, Singh K, Faisal M, Li S. Maternal methadone treatment and neonatal abstinence syndrome. *American journal of perinatology*. 2015;32(11):1078-86. doi:10.1055/s-0035-1549218.
32. Maas U, Kattner E, Weingart-Jesse B, Schafer A, Obladen M. Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy. *Journal of perinatal medicine*. 1990;18(2):111-8.
33. Gordon AL, Lopatko OV, Haslam RR, Stacey H, Pearson V, Woods A et al. Ineffective morphine treatment regimen for the control of Neonatal Abstinence Syndrome in buprenorphine- and methadone-exposed infants. *Journal of developmental origins of health and disease*. 2012;3(4):262-70. doi:10.1017/s2040174412000190.
34. Coyle MG, Salisbury AL, Lester BM, Jones HE, Lin H, Graf-Rohrmeister K et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. *Addiction (Abingdon, England)*. 2012;107 Suppl 1:63-73. doi:10.1111/j.1360-0443.2012.04040.x.
35. Berghella V, Lim PJ, Hill MK, Cherpes J, Chennat J, Kaltenbach K. Maternal methadone dose and neonatal withdrawal. *American journal of obstetrics and gynecology*. 2003;189(2):312-7.
36. Seligman NS, Almario CV, Hayes EJ, Dysart KC, Berghella V, Baxter JK. Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. *The Journal of pediatrics*. 2010;157(3):428-33. doi:10.1016/j.jpeds.2010.03.033.
37. Cleary BJ, Donnelly J, Strawbridge J, Gallagher PJ, Fahey T, Clarke M et al. Methadone dose and neonatal abstinence syndrome-systematic review and meta-analysis. *Addiction (Abingdon, England)*. 2010;105(12):2071-84. doi:10.1111/j.1360-0443.2010.03120.x.
38. O'Connor AB, O'Brien L, Alto WA. Maternal Buprenorphine Dose at Delivery and Its Relationship to Neonatal Outcomes. *European addiction research*. 2016;22(3):127-30. doi:10.1159/000441220.

39. Jones HE, Dengler E, Garrison A, O'Grady KE, Seashore C, Horton E et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. *Drug and alcohol dependence*. 2014;134:414-7. doi:10.1016/j.drugalcdep.2013.11.006.
40. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. *Drug and alcohol dependence*. 2006;82(3):250-7. doi:10.1016/j.drugalcdep.2005.10.001.
41. McCarthy JJ, Leamon MH, Willits NH, Salo R. The effect of methadone dose regimen on neonatal abstinence syndrome. *Journal of addiction medicine*. 2015;9(2):105-10. doi:10.1097/adm.0000000000000099.
42. Sabatowski R, Radbruch L, Grond S, Gohring UJ. Treatment of severe low back pain with opioids during pregnancy in a patient with incomplete tetraplegia. *Acta anaesthesiologica Scandinavica*. 2000;44(3):348-50.
43. Khan K, Chang J. Neonatal abstinence syndrome due to codeine. *Archives of disease in childhood Fetal and neonatal edition*. 1997;76(1):F59-60.
44. Mangurten HH, Benawra R. Neonatal codeine withdrawal in infants of nonaddicted mothers. *Pediatrics*. 1980;65(1):159-60.
45. Van Leeuwen G, Guthrie R, Stange F. Narcotic withdrawal reaction in a newborn infant due to codeine. *Pediatrics*. 1965;36(4):635-6.
46. Nair V, Soraisham AS, Akierman A. Neonatal withdrawal syndrome due to maternal codeine use. *Paediatrics & child health*. 2012;17(5):e40-1.
47. Reynolds EW, Riel-Romero RM, Bada HS. Neonatal abstinence syndrome and cerebral infarction following maternal codeine use during pregnancy. *Clinical pediatrics*. 2007;46(7):639-45. doi:10.1177/0009922807300795.
48. Hartenstein S, Proquitte H, Bauer S, Bamberg C, Roehr CC. Neonatal abstinence syndrome (NAS) after intrauterine exposure to tramadol. *Journal of perinatal medicine*. 2010;38(6):695-6. doi:10.1515/jpm.2010.102.
49. O'Mara K, Gal P, Davanzo C. Treatment of neonatal withdrawal with clonidine after long-term, high-dose maternal use of tramadol. *The Annals of pharmacotherapy*. 2010;44(7-8):1342-4. doi:10.1345/aph.1M758.
50. Willaschek C, Wolter E, Buchhorn R. Tramadol withdrawal in a neonate after long-term analgesic treatment of the mother. *European journal of clinical pharmacology*. 2009;65(4):429-30. doi:10.1007/s00228-008-0598-z.
51. Meyer FP, Rimasch H, Blaha B, Banditt P. Tramadol withdrawal in a neonate. *European journal of clinical pharmacology*. 1997;53(2):159-60.
52. de Wit D, Koomen-Botman I. [Neonatal abstinence syndrome after maternal use of tramadol]. *Nederlands tijdschrift voor geneeskunde*. 2013;157(9):A5610.
53. Klein RB, Blatman S, Little GA. Probable neonatal propoxyphene withdrawal: a case report. *Pediatrics*. 1975;55(6):882-4.
54. Ente G, Mehra MC. Neonatal withdrawal from propoxyphene hydrochloride. *New York state journal of medicine*. 1978;78(13):2084-5.
55. Quillian WW, 2nd, Dunn CA. Neonatal drug withdrawal from propoxyphene. *Jama*. 1976;235(19):2128.
56. Tyson HK. Neonatal withdrawal symptoms associated with maternal use of propoxyphene hydrochloride (Darvon). *The Journal of pediatrics*. 1974;85(5):684-5.
57. Regan J, Chambers F, Gorman W, MacSullivan R. Neonatal abstinence syndrome due to prolonged administration of fentanyl in pregnancy. *BJOG : an international journal of obstetrics and gynaecology*. 2000;107(4):570-2.
58. Wu WH, Teng RJ, Shin HY. Neonatal pentazocine withdrawal syndrome--a case report of conservative treatment. *Zhonghua yi xue za zhi = Chinese medical journal; Free China ed*. 1988;42(3):229-32.
59. Scanlon JW. Letter: Pentazocine and neonatal withdrawal symptoms. *The Journal of pediatrics*. 1974;85(5):735-6.
60. Goetz RL, Bain RV. Neonatal withdrawal symptoms associated with maternal use of pentazocine. *The Journal of pediatrics*. 1974;84(6):887-8.
61. Wachman EM, Hayes MJ, Lester BM, Terrin N, Brown MS, Nielsen DA et al. Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome. *The Journal of pediatrics*. 2014;165(3):472-8. doi:10.1016/j.jpeds.2014.05.040.
62. Ebner N, Rohrmeister K, Winklbaaur B, Baewert A, Jagsch R, Peternell A et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. *Drug and alcohol dependence*. 2007;87(2-3):131-8. doi:10.1016/j.drugalcdep.2006.08.024.

63. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. *Drug and alcohol dependence*. 2003;70(2 Suppl):S87-101.
64. Bio LL, Siu A, Poon CY. Update on the pharmacologic management of neonatal abstinence syndrome. *Journal of perinatology : official journal of the California Perinatal Association*. 2011;31(11):692-701. doi:10.1038/jp.2011.116.
65. Bozarth MA. Physical dependence produced by central morphine infusions: an anatomical mapping study. *Neuroscience and biobehavioral reviews*. 1994;18(3):373-83.
66. Maldonado R, Negus S, Koob GF. Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta- and kappa-selective opioid antagonists. *Neuropharmacology*. 1992;31(12):1231-41.
67. Przewlocki R. Opioid abuse and brain gene expression. *European journal of pharmacology*. 2004;500(1-3):331-49. doi:10.1016/j.ejphar.2004.07.036.
68. Stover MW, Davis JM. Opioids in pregnancy and neonatal abstinence syndrome. *Seminars in perinatology*. 2015;39(7):561-5. doi:10.1053/j.semperi.2015.08.013.
69. Wolff K, Perez-Montejano R. Opioid neonatal abstinence syndrome: controversies and implications for practice. *Current drug abuse reviews*. 2014;7(1):44-58.
70. Bagley SM, Wachman EM, Holland E, Brogly SB. Review of the assessment and management of neonatal abstinence syndrome. *Addiction science & clinical practice*. 2014;9(1):19. doi:10.1186/1940-0640-9-19.
71. Sarkar S, Donn SM. Management of neonatal abstinence syndrome in neonatal intensive care units: a national survey. *Journal of perinatology : official journal of the California Perinatal Association*. 2006;26(1):15-7. doi:10.1038/sj.jp.7211427.
72. Finnegan LP, Connaughton JF, Jr., Kron RE, Emich JP. Neonatal abstinence syndrome: assessment and management. *Addictive diseases*. 1975;2(1-2):141-58.
73. Lipsitz PJ. A proposed narcotic withdrawal score for use with newborn infants. A pragmatic evaluation of its efficacy. *Clinical pediatrics*. 1975;14(6):592-4.
74. Green M, Suffet F. The Neonatal Narcotic Withdrawal Index: a device for the improvement of care in the abstinence syndrome. *The American journal of drug and alcohol abuse*. 1981;8(2):203-13.
75. Zahorodny W, Rom C, Whitney W, Giddens S, Samuel M, Maichuk G et al. The neonatal withdrawal inventory: a simplified score of newborn withdrawal. *Journal of developmental and behavioral pediatrics : JDBP*. 1998;19(2):89-93.
76. Kraft WK, van den Anker JN. Pharmacologic management of the opioid neonatal abstinence syndrome. *Pediatric clinics of North America*. 2012;59(5):1147-65. doi:10.1016/j.pcl.2012.07.006.
77. Wachman EM, Hayes MJ, Brown MS, Paul J, Harvey-Wilkes K, Terrin N et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. *Jama*. 2013;309(17):1821-7. doi:10.1001/jama.2013.3411.
78. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. *Pediatrics*. 2006;117(6):e1163-9. doi:10.1542/peds.2005-1561.
79. McQueen KA, Murphy-Oikonen J, Gerlach K, Montelpare W. The impact of infant feeding method on neonatal abstinence scores of methadone-exposed infants. *Advances in neonatal care : official journal of the National Association of Neonatal Nurses*. 2011;11(4):282-90. doi:10.1097/ANC.0b013e318225a30c.
80. O'Connor AB, Collett A, Alto WA, O'Brien LM. Breastfeeding rates and the relationship between breastfeeding and neonatal abstinence syndrome in women maintained on buprenorphine during pregnancy. *Journal of midwifery & women's health*. 2013;58(4):383-8. doi:10.1111/jmwh.12009.
81. Welle-Strand GK, Skurtveit S, Jansson LM, Bakstad B, Bjarko L, Ravndal E. Breastfeeding reduces the need for withdrawal treatment in opioid-exposed infants. *Acta paediatrica (Oslo, Norway : 1992)*. 2013;102(11):1060-6. doi:10.1111/apa.12378.
82. Dryden C, Young D, Hepburn M, Mactier H. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. *BJOG : an international journal of obstetrics and gynaecology*. 2009;116(5):665-71. doi:10.1111/j.1471-0528.2008.02073.x.
83. Pritham UA, Paul JA, Hayes MJ. Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome. *Journal of obstetric, gynecologic, and neonatal nursing : JOGNN / NAACOG*. 2012;41(2):180-90. doi:10.1111/j.1552-6909.2011.01330.x.
84. Jansson LM, Choo R, Velez ML, Harrow C, Schroeder JR, Shakleya DM et al. Methadone maintenance and breastfeeding in the neonatal period. *Pediatrics*. 2008;121(1):106-14. doi:10.1542/peds.2007-1182.

85. Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. *The Cochrane database of systematic reviews*. 2013;12:CD006318. doi:10.1002/14651858.CD006318.pub3.
86. Hall ES, Isemann BT, Wexelblatt SL, Meinen-Derr J, Wiles JR, Harvey S et al. A Cohort Comparison of Buprenorphine versus Methadone Treatment for Neonatal Abstinence Syndrome. *The Journal of pediatrics*. 2015. doi:10.1016/j.jpeds.2015.11.039.
87. Kraft WK, Gibson E, Dysart K, Damle VS, Larusso JL, Greenspan JS et al. Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial. *Pediatrics*. 2008;122(3):e601-7. doi:10.1542/peds.2008-0571.
88. Jansson LM, Velez M, Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. *Journal of opioid management*. 2009;5(1):47-55.
89. Surran B, Visintainer P, Chamberlain S, Kopcza K, Shah B, Singh R. Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. *Journal of perinatology : official journal of the California Perinatal Association*. 2013;33(12):954-9. doi:10.1038/jp.2013.95.
90. Jackson L, Ting A, McKay S, Galea P, Skeoch C. A randomised controlled trial of morphine versus phenobarbitone for neonatal abstinence syndrome. *Archives of disease in childhood Fetal and neonatal edition*. 2004;89(4):F300-4. doi:10.1136/adc.2003.033555.
91. Langenfeld S, Birkenfeld L, Herkenrath P, Muller C, Hellmich M, Theisohn M. Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. *Drug and alcohol dependence*. 2005;77(1):31-6. doi:10.1016/j.drugalcdep.2004.07.001.
92. Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. *Addiction (Abingdon, England)*. 2011;106(3):574-80. doi:10.1111/j.1360-0443.2010.03170.x.
93. Coyle MG, Ferguson A, Lagasse L, Oh W, Lester B. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. *The Journal of pediatrics*. 2002;140(5):561-4. doi:10.1067/mpd.2002.123099.
94. Agthe AG, Kim GR, Mathias KB, Hendrix CW, Chavez-Valdez R, Jansson L et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. *Pediatrics*. 2009;123(5):e849-56. doi:10.1542/peds.2008-0978.
95. Parikh R, Hussain T, Holder G, Bhojar A, Ewer AK. Maternal methadone therapy increases QTc interval in newborn infants. *Archives of disease in childhood Fetal and neonatal edition*. 2011;96(2):F141-3. doi:10.1136/adc.2009.181701.
96. Kandall SR, Gaines J, Habel L, Davidson G, Jessop D. Relationship of maternal substance abuse to subsequent sudden infant death syndrome in offspring. *The Journal of pediatrics*. 1993;123(1):120-6.
97. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. *Jama*. 2005;293(19):2372-83. doi:10.1001/jama.293.19.2372.
98. Kieviet N, Dolman KM, Honig A. The use of psychotropic medication during pregnancy: how about the newborn? *Neuropsychiatric disease and treatment*. 2013;9:1257-66. doi:10.2147/ndt.s36394.
99. Payne JL, Meltzer-Brody S. Antidepressant use during pregnancy: current controversies and treatment strategies. *Clinical obstetrics and gynecology*. 2009;52(3):469-82. doi:10.1097/GRF.0b013e3181b52e20.
100. Olivier JD, Akerud H, Kaihola H, Pawluski JL, Skalkidou A, Hogberg U et al. The effects of maternal depression and maternal selective serotonin reuptake inhibitor exposure on offspring. *Frontiers in cellular neuroscience*. 2013;7:73. doi:10.3389/fncel.2013.00073.
101. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. *Lancet (London, England)*. 2005;365(9458):482-7. doi:10.1016/s0140-6736(05)17865-9.
102. Thormahlen GM. Paroxetine use during pregnancy: is it safe? *The Annals of pharmacotherapy*. 2006;40(10):1834-7. doi:10.1345/aph.1H116.
103. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. *The Journal of clinical psychiatry*. 2004;65(2):230-7.
104. Stahl MM, Lindquist M, Pettersson M, Edwards IR, Sanderson JH, Taylor NF et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. *European journal of clinical pharmacology*. 1997;53(3-4):163-9.

105. ter Horst PG, van der Linde S, Smit JP, den Boon J, van Lingen RA, Jansman FG et al. Clomipramine concentration and withdrawal symptoms in 10 neonates. *British journal of clinical pharmacology*. 2012;73(2):295-302. doi:10.1111/j.1365-2125.2011.04072.x.
106. Forsberg L, Naver L, Gustafsson LL, Wide K. Neonatal adaptation in infants prenatally exposed to antidepressants--clinical monitoring using Neonatal Abstinence Score. *PloS one*. 2014;9(11):e111327. doi:10.1371/journal.pone.0111327.
107. Ansary A, Ibhanebhor S, Manjunatha C. Myoclonic seizures in a preterm baby: is this a presentation of venlafaxine withdrawal? *Singapore medical journal*. 2014;55(4):e57-9.
108. Eyal R, Yaeger D. Poor neonatal adaptation after in utero exposure to duloxetine. *The American journal of psychiatry*. 2008;165(5):651. doi:10.1176/appi.ajp.2008.07071194.
109. Abdy NA, Gerhart K. Duloxetine withdrawal syndrome in a newborn. *Clinical pediatrics*. 2013;52(10):976-7. doi:10.1177/0009922812450509.
110. Alehan F, Saygi S, Tarcan A, Gurakan B. Prolonged neonatal complications after in utero exposure to fluoxetine. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2008;21(12):921-3. doi:10.1080/14767050802266899.
111. Anbu AT, Theodore A. Fluoxetine withdrawal syndrome in the newborn. *Indian pediatrics*. 2006;43(1):66-9.
112. Bellantuono C, Bozzi F, Orsolini L. Safety of escitalopram in pregnancy: a case series. *Neuropsychiatric disease and treatment*. 2013;9:1333-7. doi:10.2147/ndt.s45951.
113. Boringa JB, de Jong GM, Touw DJ. [Neonatal withdrawal symptoms following the use of clomipramine during pregnancy]. *Nederlands tijdschrift voor geneeskunde*. 1992;136(30):1473-5.
114. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. *Archives of pediatrics & adolescent medicine*. 2002;156(11):1129-32.
115. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. *Pharmacoepidemiology and drug safety*. 2007;16(10):1086-94. doi:10.1002/pds.1462.
116. de Moor RA, Mourad L, ter Haar J, Egberts AC. [Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy]. *Nederlands tijdschrift voor geneeskunde*. 2003;147(28):1370-2.
117. Leibovitch L, Rymer-Haskel N, Schushan-Eisen I, Kuint J, Strauss T, Maayan-Metzger A. Short-term neonatal outcome among term infants after in utero exposure to serotonin reuptake inhibitors. *Neonatology*. 2013;104(1):65-70. doi:10.1159/000350506.
118. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. *Archives of pediatrics & adolescent medicine*. 2006;160(2):173-6. doi:10.1001/archpedi.160.2.173.
119. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. *Acta paediatrica (Oslo, Norway : 1992)*. 2001;90(3):288-91.
120. Santos RP, Pergolizzi JJ. Transient neonatal jitteriness due to maternal use of sertraline (Zoloft). *Journal of perinatology : official journal of the California Perinatal Association*. 2004;24(6):392-4. doi:10.1038/sj.jp.7211115.
121. Cowe L, Lloyd DJ, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. *British medical journal (Clinical research ed)*. 1982;284(6332):1837-8.
122. Haddad PM, Pal BR, Clarke P, Wieck A, Sridhiran S. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome? *Journal of psychopharmacology*. 2005;19(5):554-7. doi:10.1177/0269881105056554.
123. Pakalapati RK, Bolisetty S, Austin MP, Oei J. Neonatal seizures from in utero venlafaxine exposure. *Journal of paediatrics and child health*. 2006;42(11):737-8. doi:10.1111/j.1440-1754.2006.00962.x.
124. Pogliani L, Schneider L, Dilillo D, Penagini F, Zuccotti GV. Paroxetine and neonatal withdrawal syndrome. *BMJ case reports*. 2010;2010. doi:10.1136/bcr.12.2009.2528.
125. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. *Archives of pediatrics & adolescent medicine*. 2004;158(4):312-6. doi:10.1001/archpedi.158.4.312.
126. Jaiswal S, Coombs RC, Isbister GK. Paroxetine withdrawal in a neonate with historical and laboratory confirmation. *European journal of pediatrics*. 2003;162(10):723-4. doi:10.1007/s00431-003-1293-9.

127. Murray KL, Miller KM, Pearson DL. Neonatal withdrawal syndrome following in utero exposure to paroxetine, clonazepam and olanzapine. *Journal of perinatology : official journal of the California Perinatal Association*. 2007;27(8):517-8. doi:10.1038/sj.jp.7211772.
128. Grigoriadis S, VonderPorten EH, Mamisashvili L, Eady A, Tomlinson G, Dennis CL et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. *The Journal of clinical psychiatry*. 2013;74(4):e309-20. doi:10.4088/JCP.12r07967.
129. Andrade C. The safety of duloxetine during pregnancy and lactation. *The Journal of clinical psychiatry*. 2014;75(12):e1423-7. doi:10.4088/JCP.14f09631.
130. Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA, Elliot R et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. *Pharmacopsychiatry*. 2009;42(3):95-100. doi:10.1055/s-0028-1103296.
131. Rampono J, Proud S, Hackett LP, Kristensen JH, Ilett KF. A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate. *The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)*. 2004;7(3):329-34. doi:10.1017/s1461145704004286.
132. Heikkine T, Ekblad U, Laine K. Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. *BJOG : an international journal of obstetrics and gynaecology*. 2002;109(9):1003-8.
133. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. *Journal of clinical psychopharmacology*. 1996;16(5):356-62.
134. Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. *American family physician*. 2006;74(3):449-56.
135. Ter Horst PG, Jansman FG, van Lingen RA, Smit JP, de Jong-van den Berg LT, Brouwers JR. Pharmacological aspects of neonatal antidepressant withdrawal. *Obstetrical & gynecological survey*. 2008;63(4):267-79. doi:10.1097/OGX.0b013e3181676be8.
136. Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. *Acta psychiatrica Scandinavica*. 2010;121(6):471-9. doi:10.1111/j.1600-0447.2009.01490.x.
137. Klinger G, Merlob P. Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. *The Israel journal of psychiatry and related sciences*. 2008;45(2):107-13.
138. Bot P, Semmekrot BA, van der Stappen J. Neonatal effects of exposure to selective serotonin reuptake inhibitors during pregnancy. *Archives of disease in childhood Fetal and neonatal edition*. 2006;91(2):F153. doi:10.1136/adc.2004.066431.
139. Eleftheriou G, Butera R, Cotti Cottini F, Bonati M, Farina M. Neonatal toxicity following maternal citalopram treatment. *Fetal and pediatric pathology*. 2013;32(5):362-6. doi:10.3109/15513815.2013.768743.
140. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. *Archives of general psychiatry*. 2003;60(7):720-6. doi:10.1001/archpsyc.60.7.720.
141. Koren G, Matsui D, Einarson A, Knoppert D, Steiner M. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2005;172(11):1457-9. doi:10.1503/cmaj.1041100.
142. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. *Archives of general psychiatry*. 2006;63(8):898-906. doi:10.1001/archpsyc.63.8.898.
143. Klinger G, Frankenthal D, Merlob P, Diamond G, Sirota L, Levinson-Castiel R et al. Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. *Journal of perinatology : official journal of the California Perinatal Association*. 2011;31(9):615-20. doi:10.1038/jp.2010.211.
144. Ferreira E, Carceller AM, Agogue C, Martin BZ, St-Andre M, Francoeur D et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. *Pediatrics*. 2007;119(1):52-9. doi:10.1542/peds.2006-2133.
145. Jefferies AL. Selective serotonin reuptake inhibitors in pregnancy and infant outcomes. *Paediatrics & child health*. 2011;16(9):562-3.
146. Tuccori M, Testi A, Antonioli L, Fornai M, Montagnani S, Ghisu N et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. *Clinical therapeutics*. 2009;31 Pt 1:1426-53. doi:10.1016/j.clinthera.2009.07.009.

147. Morris R, Matthes J. Serotonin syndrome in a breast-fed neonate. *BMJ case reports*. 2015;2015. doi:10.1136/bcr-2015-209418.
148. Ahmed M, Parameshwaran A, Swamy P. Neonatal convulsions secondary to paroxetine withdrawal. *JPMMA The Journal of the Pakistan Medical Association*. 2007;57(3):162.
149. Hendrick V, Stowe ZN, Altshuler LL, Mintz J, Hwang S, Hostetter A et al. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. *Biological psychiatry*. 2001;50(10):775-82.
150. Boyce PM, Hackett LP, Ilett KF. Duloxetine transfer across the placenta during pregnancy and into milk during lactation. *Archives of women's mental health*. 2011;14(2):169-72. doi:10.1007/s00737-011-0215-5.
151. Briggs GG, Ambrose PJ, Ilett KF, Hackett LP, Nageotte MP, Padilla G. Use of duloxetine in pregnancy and lactation. *The Annals of pharmacotherapy*. 2009;43(11):1898-902. doi:10.1345/aph.1M317.
152. Coban D, Kurtoglu S, Akin MA, Akcakus M, Gunes T. Neonatal episodic hypoglycemia: a finding of valproic acid withdrawal. *Journal of clinical research in pediatric endocrinology*. 2010;2(2):92-4. doi:10.4274/jcrpe.v2i2.92.
153. Burja S, Rakovec-Felser Z, Treiber M, Hajdinjak D, Gajsek-Marchetti M. The frequency of neonatal morbidity after exposure to antiepileptic drugs in utero: a retrospective population-based study. *Wiener klinische Wochenschrift*. 2006;118 Suppl 2:12-6. doi:10.1007/s00508-006-0539-8.
154. Dean JC, Moore SJ, Turnpenny PD. Developing diagnostic criteria for the fetal anticonvulsant syndromes. *Seizure*. 2000;9(3):233-4. doi:10.1053/seiz.2000.0392.
155. Dean JC, Hailey H, Moore SJ, Lloyd DJ, Turnpenny PD, Little J. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. *Journal of medical genetics*. 2002;39(4):251-9.
156. Borthen I, Eide MG, Veiby G, Daltveit AK, Gilhus NE. Complications during pregnancy in women with epilepsy: population-based cohort study. *BJOG : an international journal of obstetrics and gynaecology*. 2009;116(13):1736-42. doi:10.1111/j.1471-0528.2009.02354.x.
157. Brosh K, Matok I, Sheiner E, Koren G, Wiznitzer A, Gorodischer R et al. Teratogenic determinants of first-trimester exposure to antiepileptic medications. *Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique*. 2011;18:e89-98.
158. Bech BH, Kjaersgaard MI, Pedersen HS, Howards PP, Sorensen MJ, Olsen J et al. Use of antiepileptic drugs during pregnancy and risk of spontaneous abortion and stillbirth: population based cohort study. *BMJ (Clinical research ed)*. 2014;349:g5159. doi:10.1136/bmj.g5159.
159. Bobo WV, Davis RL, Toh S, Li DK, Andrade SE, Cheetham TC et al. Trends in the use of antiepileptic drugs among pregnant women in the US, 2001-2007: a medication exposure in pregnancy risk evaluation program study. *Paediatric and perinatal epidemiology*. 2012;26(6):578-88. doi:10.1111/ppe.12004.
160. Wen X, Meador KJ, Hartzema A. Antiepileptic drug use by pregnant women enrolled in Florida Medicaid. *Neurology*. 2015;84(9):944-50. doi:10.1212/wnl.0000000000001304.
161. Utilization of antiepileptic drugs during pregnancy: comparative patterns in 38 countries based on data from the EURAP registry. *Epilepsia*. 2009;50(10):2305-9. doi:10.1111/j.1528-1167.2009.02093.x.
162. Vajda FJ, Hollingworth S, Graham J, Hitchcock AA, O'Brien TJ, Lander CM et al. Changing patterns of antiepileptic drug use in pregnant Australian women. *Acta neurologica Scandinavica*. 2010;121(2):89-93. doi:10.1111/j.1600-0404.2009.01260.x.
163. Meador KJ. Effects of in utero antiepileptic drug exposure. *Epilepsy currents / American Epilepsy Society*. 2008;8(6):143-7. doi:10.1111/j.1535-7511.2008.00273.x.
164. Crawford P. Best practice guidelines for the management of women with epilepsy. *Epilepsia*. 2005;46 Suppl 9:117-24. doi:10.1111/j.1528-1167.2005.00323.x.
165. D'Souza SW, Robertson IG, Donnai D, Mawer G. Fetal phenytoin exposure, hypoplastic nails, and jitteriness. *Archives of disease in childhood*. 1991;66(3):320-4.
166. Koch S, Jager-Roman E, Losche G, Nau H, Rating D, Helge H. Antiepileptic drug treatment in pregnancy: drug side effects in the neonate and neurological outcome. *Acta paediatrica (Oslo, Norway : 1992)*. 1996;85(6):739-46.
167. Ebbesen F, Joergensen A, Hoseth E, Kaad PH, Moeller M, Holsteen V et al. Neonatal hypoglycaemia and withdrawal symptoms after exposure in utero to valproate. *Archives of disease in childhood Fetal and neonatal edition*. 2000;83(2):F124-9.
168. Nau H, Rating D, Koch S, Hauser I, Helge H. Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother's milk and clinical status in neonates of epileptic mothers. *The Journal of pharmacology and experimental therapeutics*. 1981;219(3):768-77.
169. Thisted E, Ebbesen F. Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. *Archives of disease in childhood*. 1993;69(3 Spec No):288-91.

170. Duncan SD, Devlin LA. Use of baclofen for withdrawal in a preterm infant. *Journal of perinatology : official journal of the California Perinatal Association*. 2013;33(4):327-8. doi:10.1038/jp.2012.107.
171. Ratnayaka BD, Dhaliwal H, Watkin S. Drug points: Neonatal convulsions after withdrawal of baclofen. *BMJ (Clinical research ed)*. 2001;323(7304):85.
172. Greene CM, Goodman MH. Neonatal abstinence syndrome: strategies for care of the drug-exposed infant. *Neonatal network : NN*. 2003;22(4):15-25. doi:10.1891/0730-0832.22.4.15.
173. Koch S, Gopfert-Geyer I, Jager-Roman E, Jakob S, Huth H, Hartmann A et al. [Anti-epileptic agents during pregnancy. A prospective study on the course of pregnancy, malformations and child development]. *Deutsche medizinische Wochenschrift (1946)*. 1983;108(7):250-7. doi:10.1055/s-2008-1069536.
174. Rolnitsky A, Merlob P, Klinger G. In utero oxcarbazepine and a withdrawal syndrome, anomalies, and hyponatremia. *Pediatric neurology*. 2013;48(6):466-8. doi:10.1016/j.pediatrneurol.2013.02.012.
175. Vieker S, Thiel M, Langler A. [Neonatal seizures caused by lamotrigine withdrawal?]. *Zeitschrift für Geburtshilfe und Neonatologie*. 2009;213(2):62-3. doi:10.1055/s-0029-1214404.
176. Carrasco M, Rao SC, Bearer CF, Sundararajan S. Neonatal Gabapentin Withdrawal Syndrome. *Pediatric neurology*. 2015;53(5):445-7. doi:10.1016/j.pediatrneurol.2015.06.023.
177. Tomson T. Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. *Therapeutic drug monitoring*. 2005;27(6):718-21.
178. Ishizaki T, Yokochi K, Chiba K, Tabuchi T, Wagatsuma T. Placental transfer of anticonvulsants (phenobarbital, phenytoin, valproic acid) and the elimination from neonates. *Pediatric pharmacology (New York, NY)*. 1981;1(4):291-303.
179. Semczuk-Sikora A, Czuczwar S, Semczuk A, Kwasniewska A, Semczuk M. Valproic acid transfer across human placental cotyledon during dual perfusion in vitro. *Annals of agricultural and environmental medicine : AAEM*. 2010;17(1):153-7.
180. Ohman I, Vitols S, Tomson T. Pharmacokinetics of gabapentin during delivery, in the neonatal period, and lactation: does a fetal accumulation occur during pregnancy? *Epilepsia*. 2005;46(10):1621-4. doi:10.1111/j.1528-1167.2005.00251.x.
181. Kuhn W, Koch S, Helge H, Nau H. Primidone and phenobarbital during lactation period in epileptic women: total and free drug serum levels in the nursed infants and their effects on neonatal behavior. *Developmental pharmacology and therapeutics*. 1988;11(3):147-54.
182. Tran KT, Hranicky D, Lark T, Jacob N. Gabapentin withdrawal syndrome in the presence of a taper. *Bipolar disorders*. 2005;7(3):302-4. doi:10.1111/j.1399-5618.2005.00200.x.
183. Leo RJ, Baer D. Delirium associated with baclofen withdrawal: a review of common presentations and management strategies. *Psychosomatics*. 2005;46(6):503-7. doi:10.1176/appi.psy.46.6.503.
184. Asai M, Talavera E, Massarini A, Zubieta M, Vindrola O. Valproic acid-induced rapid changes of met-enkephalin levels in rat brain. Probable association with abstinence behavior and anticonvulsant activity. *Neuropeptides*. 1994;27(3):203-10.
185. Duncan JS, Shorvon SD, Trimble MR. Discontinuation of phenytoin, carbamazepine, and valproate in patients with active epilepsy. *Epilepsia*. 1990;31(3):324-33.
186. Jalling B, Boreus LO, Kallberg N, Agurell S. Disappearance from the newborn of circulating prenatally administered phenobarbital. *European journal of clinical pharmacology*. 1973;6(4):234-8.
187. Desmond MM, Schwanecke RP, Wilson GS, Yasunaga S, Burgdorff I. Maternal barbiturate utilization and neonatal withdrawal symptomatology. *The Journal of pediatrics*. 1972;80(2):190-7.
188. Zuppa AA, Carducci C, Scorrano A, Antichi E, Catenazzi P, Piras A et al. Infants born to mothers under phenobarbital treatment: correlation between serum levels and clinical features of neonates. *European journal of obstetrics, gynecology, and reproductive biology*. 2011;159(1):53-6. doi:10.1016/j.ejogrb.2011.06.035.
189. Zhang LL, Zeng LN, Li YP. Side effects of phenobarbital in epilepsy: a systematic review. *Epileptic disorders : international epilepsy journal with videotape*. 2011;13(4):349-65. doi:10.1684/epd.2011.0444.
190. Bleyer WA, Marshall RE. Barbiturate withdrawal syndrome in a passively addicted infant. *Jama*. 1972;221(2):185-6.
191. Blumenthal I, Lindsay S. Neonatal barbiturate withdrawal. *Postgraduate medical journal*. 1977;53(617):157-8.
192. Erith MJ. Letter: Withdrawal symptoms in newborn infants of epileptic mothers. *British medical journal*. 1975;3(5974):40.
193. Neonatal behaviour and maternal barbiturates. *British medical journal*. 1972;4(5832):63-4.
194. Ploman L, Persson BH. On the transfer of barbiturates to the human foetus and their accumulation in some of its vital organs. *The Journal of obstetrics and gynaecology of the British Empire*. 1957;64(5):706-11.

195. Melchior JC, Svensmark O, Trolle D. Placental transfer of phenobarbitone in epileptic women, and elimination in newborns. *Lancet* (London, England). 1967;2(7521):860-1.
196. Davanzo R, Dal Bo S, Bua J, Copertino M, Zanelli E, Matarazzo L. Antiepileptic drugs and breastfeeding. *Italian journal of pediatrics*. 2013;39:50. doi:10.1186/1824-7288-39-50.
197. Bidlack JM, Morris HH, 3rd. Phenobarbital withdrawal seizures may occur over several weeks before remitting: human data and hypothetical mechanism. *Seizure*. 2009;18(1):79-81. doi:10.1016/j.seizure.2008.06.014.
198. Bergman U, Rosa FW, Baum C, Wiholm BE, Faich GA. Effects of exposure to benzodiazepine during fetal life. *Lancet* (London, England). 1992;340(8821):694-6.
199. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. *Psychiatric services* (Washington, DC). 2002;53(1):39-49. doi:10.1176/appi.ps.53.1.39.
200. McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. *Reproductive toxicology* (Elmsford, NY). 1994;8(6):461-75.
201. Addis A, Dolovich LR, Einarson TR, Koren G. Can we use anxiolytics during pregnancy without anxiety? *Canadian family physician Medecin de famille canadien*. 2000;46:549-51.
202. Kocherlakota P. Neonatal abstinence syndrome. *Pediatrics*. 2014;134(2):e547-61. doi:10.1542/peds.2013-3524.
203. Lendoiro E, Gonzalez-Colmenero E, Concheiro-Guisan A, de Castro A, Cruz A, Lopez-Rivadulla M et al. Maternal hair analysis for the detection of illicit drugs, medicines, and alcohol exposure during pregnancy. *Therapeutic drug monitoring*. 2013;35(3):296-304. doi:10.1097/FTD.0b013e318288453f.
204. Wikner BN, Stiller CO, Bergman U, Asker C, Kallen B. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. *Pharmacoepidemiology and drug safety*. 2007;16(11):1203-10. doi:10.1002/pds.1457.
205. McGrath C, Buist A, Norman TR. Treatment of anxiety during pregnancy: effects of psychotropic drug treatment on the developing fetus. *Drug safety*. 1999;20(2):171-86.
206. Uzun S, Kozumplik O, Jakovljevic M, Sedic B. Side effects of treatment with benzodiazepines. *Psychiatria Danubina*. 2010;22(1):90-3.
207. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. *Obstetrics and gynecology*. 2008;111(4):1001-20. doi:10.1097/AOG.0b013e31816fd910.
208. Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. *BMJ* (Clinical research ed). 1998;317(7162):839-43.
209. Richard P, Autret E, Bardol J, Soyez C, Barbier P, Jonville AP et al. The use of flumazenil in a neonate. *Journal of toxicology Clinical toxicology*. 1991;29(1):137-40.
210. Swortfiguer D, Cissoko H, Giraudeau B, Jonville-Bera AP, Bensouda L, Autret-Leca E. [Neonatal consequences of benzodiazepines used during the last month of pregnancy]. *Archives de pediatrie : organe officiel de la Societe francaise de pediatrie*. 2005;12(9):1327-31. doi:10.1016/j.arcped.2005.03.055.
211. Lind JN, Petersen EE, Lederer PA, Phillips-Bell GS, Perrine CG, Li R et al. Infant and maternal characteristics in neonatal abstinence syndrome--selected hospitals in Florida, 2010-2011. *MMWR Morbidity and mortality weekly report*. 2015;64(8):213-6.
212. Drury KA, Spalding E, Donaldson D, Rutherford D. Floppy-infant syndrome: Is oxazepam the answer? *Lancet* (London, England). 1977;2(8048):1126-7.
213. McBride RJ, Dundee JW, Moore J, Toner W, Howard PJ. A study of the plasma concentrations of lorazepam in mother and neonate. *British journal of anaesthesia*. 1979;51(10):971-8.
214. Weinstock L, Cohen LS, Bailey JW, Blatman R, Rosenbaum JF. Obstetrical and neonatal outcome following clonazepam use during pregnancy: a case series. *Psychotherapy and psychosomatics*. 2001;70(3):158-62. doi:56242.
215. Decancq HG, Jr., Bosco JR, Townsend EH, Jr. Chlordiazepoxide in labor. Its effect on the newborn infant. *The Journal of pediatrics*. 1965;67(5):836-40.
216. Haram K. "Floppy infant syndrome" and maternal diazepam. *Lancet* (London, England). 1977;2(8038):612-3.
217. Crawford JS. Premedication for elective Caesarean section. *Anaesthesia*. 1979;34(9):892-7.
218. Gitsch E, Philipp K, Schonbauer M. [Intranatal Administration of midazolam (author's transl)]. *Zeitschrift fur Geburtshilfe und Perinatologie*. 1982;186(1):46-9.

219. Shader RI. Is there anything new on the use of psychotropic drugs during pregnancy? *Journal of clinical psychopharmacology*. 1994;14(6):438.
220. Barry WS, St Clair SM. Exposure to benzodiazepines in utero. *Lancet (London, England)*. 1987;1(8547):1436-7.
221. Bitnun S. Possible effect of chlordiazepoxide on the fetus. *Canadian Medical Association journal*. 1969;100(7):351.
222. Bellantuono C, Orsolini L, Bozzi F. [The safety profile of escitalopram in pregnancy and breastfeeding]. *Rivista di psichiatria*. 2013;48(6):407-14. doi:10.1708/1379.15335.
223. Cone AM, Nadel S, Sweeney B. Flumazenil reverses diazepam-induced neonatal apnoea and hypotonia. *European journal of pediatrics*. 1993;152(5):458-9.
224. Di Michele V, Ramenghi L, Sabatino G. Clozapine and lorazepam administration in pregnancy. *European psychiatry : the journal of the Association of European Psychiatrists*. 1996;11(4):214. doi:10.1016/0924-9338(96)88396-9.
225. Garcia-Algar O, Lopez-Vilchez MA, Martin I, Mur A, Pellegrini M, Pacifici R et al. Confirmation of gestational exposure to alprazolam by analysis of biological matrices in a newborn with neonatal sepsis. *Clinical toxicology (Philadelphia, Pa)*. 2007;45(3):295-8. doi:10.1080/15563650601072191.
226. Gillberg C. "Floppy infant syndrome" and maternal diazepam. *Lancet (London, England)*. 1977;2(8031):244.
227. Rementeria JL, Bhatt K. Withdrawal symptoms in neonates from intrauterine exposure to diazepam. *The Journal of pediatrics*. 1977;90(1):123-6.
228. Speight AN. Floppy-infant syndrome and maternal diazepam and/or nitrazepam. *Lancet (London, England)*. 1977;2(8043):878.
229. Fisher JB, Edgren BE, Mammel MC, Coleman JM. Neonatal apnea associated with maternal clonazepam therapy: a case report. *Obstetrics and gynecology*. 1985;66(3 Suppl):34s-5s.
230. Rane A, Sundwall A, Tomson G. [Oxazepam withdrawal in the neonatal period]. *Lakartidningen*. 1979;76(48):4416-7.
231. Mazzi E. Possible neonatal diazepam withdrawal: a case report. *American journal of obstetrics and gynecology*. 1977;129(5):586-7.
232. Backes CR, Cordero L. Withdrawal symptoms in the neonate from presumptive intrauterine exposure to diazepam: report of case. *The Journal of the American Osteopathic Association*. 1980;79(9):584-5.
233. Athinarayanan P, Pierog SH, Nigam SK, Glass L. Chlordiazepoxide withdrawal in the neonate. *American journal of obstetrics and gynecology*. 1976;124(2):212-3.
234. Gonzalez de Dios J, Moya-Benavent M, Carratala-Marco F. ["Floppy infant" syndrome in twins secondary to the use of benzodiazepines during pregnancy]. *Revista de neurologia*. 1999;29(2):121-3.
235. Stirrat GM, Edington PT, Berry DJ. Letter: Transplacental passage of chlordiazepoxide. *British medical journal*. 1974;2(5921):729.
236. Kriel RL, Cloyd J. Clonazepam and pregnancy. *Annals of neurology*. 1982;11(5):544. doi:10.1002/ana.410110518.
237. Anderson PO, McGuire GG. Neonatal alprazolam withdrawal--possible effects of breast feeding. *DICP : the annals of pharmacotherapy*. 1989;23(7-8):614.
238. Shannon RW, Fraser GP, Aitken RG, Harper JR. Diazepam in preeclamptic toxemia with special reference to its effect on the newborn infant. *The British journal of clinical practice*. 1972;26(6):271-5.
239. Woods DL, Malan AF. Side-effects of maternal diazepam on the newborn infant. *South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde*. 1978;54(16):636.
240. Bavoux F, Lanfranchi C, Olive G, Asensi D, Dulac O, Francoual C et al. [Adverse effects on newborns from intra uterine exposure to benzodiazepines and other psychotropic agents (author's transl)]. *Therapie*. 1981;36(3):305-12.
241. Flowers CE, Rudolph AJ, Desmond MM. Diazepam (valium) as an adjunct in obstetric analgesia. *Obstetrics and gynecology*. 1969;34(1):68-81.
242. Nisbet R, Boulas SH, Kantor HI. Diazepam (valium) during labor. *Obstetrics and gynecology*. 1967;29(5):726-9.
243. McCarthy GT, O'Connell B, Robinson AE. Blood levels of diazepam in infants of two mothers given large doses of diazepam during labour. *The Journal of obstetrics and gynaecology of the British Commonwealth*. 1973;80(4):349-52.
244. Owen JR, Irani SF, Blair AW. Effect of diazepam administered to mothers during labour on temperature regulation of neonate. *Archives of disease in childhood*. 1972;47(251):107-10.

245. Cree JE, Meyer J, Hailey DM. Diazepam in labour: its metabolism and effect on the clinical condition and thermogenesis of the newborn. *British medical journal*. 1973;4(5887):251-5.
246. McAuley DM, O'Neill MP, Moore J, Dundee JW. Lorazepam premedication for labour. *British journal of obstetrics and gynaecology*. 1982;89(2):149-54.
247. Whitelaw AG, Cummings AJ, McFadyen IR. Effect of maternal lorazepam on the neonate. *British medical journal (Clinical research ed)*. 1981;282(6270):1106-8.
248. Neonatal drug withdrawal. American Academy of Pediatrics Committee on Drugs. *Pediatrics*. 1998;101(6):1079-88.
249. Kanto JH. Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations. *Drugs*. 1982;23(5):354-80.
250. Weintraub Z, Bental Y, Oliven A, Rotschild A. Neonatal withdrawal syndrome and behavioral effects produced by maternal drug use. *Addiction biology*. 1998;3(2):159-70. doi:10.1080/13556219872227.
251. Potokar J, Coupland N, Wilson S, Rich A, Nutt D. Assessment of GABA(A)benzodiazepine receptor (GBzR) sensitivity in patients on benzodiazepines. *Psychopharmacology*. 1999;146(2):180-4.
252. Marriott S, Tyrer P. Benzodiazepine dependence. Avoidance and withdrawal. *Drug safety*. 1993;9(2):93-103.
253. Stahl MM, Saldeen P, Vinge E. Reversal of fetal benzodiazepine intoxication using flumazenil. *British journal of obstetrics and gynaecology*. 1993;100(2):185-8.
254. Schmidt B, Kirpalani H, Rosenbaum P, Cadman D. Strengths and limitations of the Apgar score: a critical appraisal. *Journal of clinical epidemiology*. 1988;41(9):843-50.
255. Odegard O. Fertility of psychiatric first admissions in Norway 1936-1975. *Acta psychiatrica Scandinavica*. 1980;62(3):212-20.
256. Miller WH, Jr., Bloom JD, Resnick MP. Prenatal care for pregnant chronic mentally ill patients. *Hospital & community psychiatry*. 1992;43(9):942-3.
257. Castle DJ MJ, Kulkarni J. . Reproductive, preconceptional and antenatal needs of women with schizophrenia. *Women and Schizophrenia*. . Cambridge, UK: Cambridge University Press. 2000.
258. Taylor D, Paton, C., & Kapur, S. . Prescribing guidelines in psychiatry (11th ed.). Cornwall, UK: A John Wiley & Sons. 2012.
259. Torre DL, Falorni A. Pharmacological causes of hyperprolactinemia. *Therapeutics and clinical risk management*. 2007;3(5):929-51.
260. McNeil TF, Kaij L, Malmquist-Larsson A. Women with nonorganic psychosis: pregnancy's effect on mental health during pregnancy. *Acta psychiatrica Scandinavica*. 1984;70(2):140-8.
261. Coverdale JH, Turbott SH, Roberts H. Family planning needs and STD risk behaviours of female psychiatric out-patients. *The British journal of psychiatry : the journal of mental science*. 1997;171:69-72.
262. Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. *Bipolar disorders*. 2004;6(1):2-13.
263. AC. S. Special needs of women with bipolar disorder. . IntellystMedical Communication International Congress on Women's Mental Health; 17-20 March 2004; Washington, DC 2004:4-18.
264. Grof P, Robbins W, Alda M, Berghoefer A, Vojtechovsky M, Nilsson A et al. Protective effect of pregnancy in women with lithium-responsive bipolar disorder. *Journal of affective disorders*. 2000;61(1-2):31-9.
265. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. *The British journal of psychiatry : the journal of mental science*. 1987;150:662-73.
266. Pugh TF, Jerath BK, Schmidt WM, Reed RB. Rates of mental disease related to childbearing. *The New England journal of medicine*. 1963;268:1224-8. doi:10.1056/NEJM196305302682205.
267. Videbech P, Gouliaev G. First admission with puerperal psychosis: 7-14 years of follow-up. *Acta psychiatrica Scandinavica*. 1995;91(3):167-73.
268. Freeman MP, Smith KW, Freeman SA, McElroy SL, Kmetz GE, Wright R et al. The impact of reproductive events on the course of bipolar disorder in women. *The Journal of clinical psychiatry*. 2002;63(4):284-7.
269. Gentile S. Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights. *CNS drugs*. 2007;21(5):367-87.
270. Epstein RA, Bobo WV, Shelton RC, Arbogast PG, Morrow JA, Wang W et al. Increasing use of atypical antipsychotics and anticonvulsants during pregnancy. *Pharmacoepidemiology and drug safety*. 2013;22(7):794-801. doi:10.1002/pds.3366.

271. Einarson A, Boskovic R. Use and safety of antipsychotic drugs during pregnancy. *Journal of psychiatric practice*. 2009;15(3):183-92. doi:10.1097/01.pra.0000351878.45260.94.
272. Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review. *Schizophrenia bulletin*. 2010;36(3):518-44. doi:10.1093/schbul/sbn107.
273. Reis M, Kallen B. Maternal use of antipsychotics in early pregnancy and delivery outcome. *Journal of clinical psychopharmacology*. 2008;28(3):279-88. doi:10.1097/JCP.0b013e318172b8d5.
274. Johnson KC, LaPrairie JL, Brennan PA, Stowe ZN, Newport DJ. Prenatal antipsychotic exposure and neuromotor performance during infancy. *Archives of general psychiatry*. 2012;69(8):787-94. doi:10.1001/archgenpsychiatry.2012.160.
275. Auerbach JG, Hans SL, Marcus J, Maeir S. Maternal psychotropic medication and neonatal behavior. *Neurotoxicology and teratology*. 1992;14(6):399-406.
276. U.S. Food and Drug Administration. FDA drug safety communication: antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns. 2011.
277. Kulkarni J, Worsley R, Gilbert H, Gavrilidis E, Van Rheenen TE, Wang W et al. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. *PloS one*. 2014;9(5):e94788. doi:10.1371/journal.pone.0094788.
278. McKenna K, Koren G, Tetelbaum M, Wilton L, Shakir S, Diav-Citrin O et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. *The Journal of clinical psychiatry*. 2005;66(4):444-9; quiz 546.
279. Kim SW, Kim KM, Kim JM, Shin IS, Shin HY, Yang SJ et al. Use of long-acting injectable risperidone before and throughout pregnancy in schizophrenia. *Progress in neuro-psychopharmacology & biological psychiatry*. 2007;31(2):543-5. doi:10.1016/j.pnpbp.2006.09.017.
280. McCauley-Elsom K, Kulkarni J. Managing psychosis in pregnancy. *The Australian and New Zealand journal of psychiatry*. 2007;41(3):289-92. doi:10.1080/00048670601172798.
281. Coppola D, Russo LJ, Kwarta RF, Jr., Varughese R, Schmider J. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes. *Drug safety*. 2007;30(3):247-64.
282. Nako Y, Tachibana A, Fujiu T, Tomomasa T, Morikawa A. Neonatal thrombocytosis resulting from the maternal use of non-narcotic antischizophrenic drugs during pregnancy. *Archives of disease in childhood Fetal and neonatal edition*. 2001;84(3):F198-200.
283. Gilad O, Merlob P, Stahl B, Klinger G. Outcome of infants exposed to olanzapine during breastfeeding. *Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine*. 2011;6(2):55-8. doi:10.1089/bfm.2010.0027.
284. S. B. Psychotropic Drug Directory. . Salisbury, UK: Fivepin Limited; . 2005;235.
285. Dev VJ KP. Adverse event profile and safety of clozapine. . *Rev Contemp Pharmacother*. 1995;6:197-208.
286. Vavrusova L KM. Clozapine administration during pregnancy [in Czechoslovakian]. . *Ceska Slov Psychiatr* 1998;94:282-5.
287. Mendhekar DN, Sharma JB, Srivastava PK, War L. Clozapine and pregnancy. *The Journal of clinical psychiatry*. 2003;64(7):850.
288. Karakula H, Szajer K, Rpila B, Grzywa A, Chuchra M. Clozapine and pregnancy--a case history. *Pharmacopsychiatry*. 2004;37(6):303-4. doi:10.1055/s-2004-832689.
289. Stoner SC, Sommi RW, Jr., Marken PA, Anya I, Vaughn J. Clozapine use in two full-term pregnancies. *The Journal of clinical psychiatry*. 1997;58(8):364-5.
290. Yogev Y, Ben-Haroush A, Kaplan B. Maternal clozapine treatment and decreased fetal heart rate variability. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics*. 2002;79(3):259-60.
291. Biswasl PN, Wilton LV, Pearcel GL, Freemantle S, Shakir SA. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. *Journal of psychopharmacology*. 2001;15(4):265-71.
292. Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. *Journal of clinical psychopharmacology*. 2000;20(4):399-403.
293. O'Connor M, Johnson GH, James DI. Intrauterine effect of phenothiazines. *The Medical journal of Australia*. 1981;1(8):416-7.
294. Cleary MF. Fluphenazine decanoate during pregnancy. *The American journal of psychiatry*. 1977;134(7):815-6. doi:10.1176/ajp.134.7.815.

295. Nath SP, Miller DA, Muraskas JK. Severe rhinorrhea and respiratory distress in a neonate exposed to fluphenazine hydrochloride prenatally. *The Annals of pharmacotherapy*. 1996;30(1):35-7.
296. Iqbal MM, Aneja A, Rahman A, Megna J, Freemont W, Shiplo M et al. The potential risks of commonly prescribed antipsychotics: during pregnancy and lactation. *Psychiatry*. 2005;2(8):36-44.
297. Newport DJ, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. *The American journal of psychiatry*. 2007;164(8):1214-20. doi:10.1176/appi.ajp.2007.06111886.
298. Gardos G, Cole JO, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. *The American journal of psychiatry*. 1978;135(11):1321-4. doi:10.1176/ajp.135.11.1321.
299. Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. *The American journal of psychiatry*. 1980;137(11):1395-8. doi:10.1176/ajp.137.11.1395.
300. Worsley R, Gilbert H, Gavrilidis E, Naughton B, Kulkarni J. Breastfeeding and psychotropic medications. *Lancet (London, England)*. 2013;381(9870):905. doi:10.1016/s0140-6736(13)60671-6.
301. Boutroy MJ, Gissonna CR, Legagneur M. Clonidine: placental transfer and neonatal adaptation. *Early human development*. 1988;17(2-3):275-86.
302. Prenner BM. Neonatal withdrawal syndrome associated with hydroxyzine hydrochloride. *American journal of diseases of children (1960)*. 1977;131(5):529-30.
303. Serreau R, Komiha M, Blanc F, Guillot F, Jacqz-Aigrain E. Neonatal seizures associated with maternal hydroxyzine hydrochloride in late pregnancy. *Reproductive toxicology (Elmsford, NY)*. 2005;20(4):573-4. doi:10.1016/j.reprotox.2005.03.005.
304. Shimohira M, Iwakawa Y, Kohyama J. Rapid-eye-movement sleep in jittery infants. *Early human development*. 2002;66(1):25-31.
305. South M. Neonatal seizures after use of pyridoxine in pregnancy. *Lancet (London, England)*. 1999;353(9168):1940-1.

Table 1. Prescription drug classes most frequently associated with drug-induced neonatal syndromes

Drug class	Neonatal abstinence syndrome		Residual pharmacological effects	
	Symptoms	Onset since delivery	Symptoms	Onset since delivery
Opioids	Congestion, diarrhea, feeding disorders, fever, hypertonia, hyperreflexia, insomnia, irritability, seizure, sweating, tachypnea, tremors, vomiting	Methadone: 60 hours Buprenorphine: 12-48 hours Morphine: 36 hours Tramadol: 35-48 hours Codeine: 2 hours Fentanyl: 24 hours	Rarely described (i.e. methadone-induced QT interval prolongation)	Not assessed
Antidepressants	Chills, feeding disorders, hypotonia, hypertonia, irritability, jaundice, persistent crying, respiratory distress, restlessness, seizures, sleep disorders, tachypnea, tremors, vomiting	Within 24-72 hours	Withdrawal-like effects TCAs: Anticholinergic effects (constipation, urinary retention) SSRIs: serotonin-like symptoms (fever, myoclonus, tremors)	First hours
AEDs	Abnormal tone, apnea, feeding disorders, hypoglycemia, hypotonia, irritability, jitteriness, seizures, vomiting	First hours up to one week	Feeding disorders, hypoglycaemia (VPA), hypotonia, sedation	First hours
Barbiturates	Feeding disorders, hiccups and mouthing, hyperacusia, hyperphagia, hypotonia, irritability, jitteriness, persistent crying, sleep disorders, seizures, sweating, tremors, vomiting	6 days (average) (from 30 minutes to 14 days)	Not assessed	Not assessed
BZDs	Feeding disorders, hyperactivity, hypertonicity, irritability, loose stools, poor tachypnea, tremors, vomiting, weight gain	First hours up to three weeks	Apnea, CNS depression, cyanosis, feeding disorders, hyperbilirubinemia, hypothermia, hypotonia, inactivity, low Apgar score, lethargy, weak crying	First hours
Antipsychotics	Agitation, feeding disorders, hypertonia, hypotonia, respiratory distress, somnolence, tremors	First hours to one month	Withdrawal-like effects	Not assessed

AEDs: antiepileptic drugs; BZDs: benzodiazepines; TCAs: tricyclic antidepressants; SSRIs: selective serotonin reuptake inhibitors; VPA: valproic acid; CNS: central nervous system

Table 2. Neonatal abstinence syndrome score. This tool assigns a cumulative score based on interval observation of several items related to signs of neonatal withdrawal.[88]

Group	Signs and symptoms	Description and scores
Neurologic hyperexcitability	Excessive crying	Score 2: infants who cannot stop crying and are difficult to console; score 3: infants who cannot stop crying with comfort measures
	Sleeping	The longest amount of time that the infant sleeps continuously between feeding and scoring periods. Score 0: > 3 hours; score 1: 2-3 hours; score 2: 1-2 hours; score 3: < 1 hour
	Moro reflex	Score 2: hyperactive response with excessive abduction at the shoulder and extension at the elbow; score 3: the above signs occurred with marked adduction flexion at the elbow with arms crossing the midline
	Tremors disturbed (stimulated)	Score 1: mild tremors, occurring frequently in fussy or crying states and occasionally in quiet alert states; score 2: moderate to severe tremors occurring occasionally in drowsy states, often in quiet alert states and consistently in fussy or crying states
	Tremors undisturbed (not stimulated)	
	Increased muscle tone (hypertonia)	Tone is the resistance of parts of the body to passive movements and can be assessed by testing the infant's motor resistance. Score 1: generalized increased resistance to extension and flexion of the limbs and head lag on pull to sit; score 2: exaggerated increased tone, sometimes visible without handling, with difficulty in straightening or bending the arms with or without head lag (or chin tuck) on pull to sit
	Excoriation	Excoriation is redness or a superficial lesion of the skin that results from the rubbing on linen due to excessive and uncontrolled movements of the extremities (tremors) and head (rooting). Score 1: skin is red but intact; score 2: skin is broken
Autonomic dysregulation	Generalized seizure	Score 8: presence of seizure activity
	Sweating	Score 1: dampness of the infant's forehead or upper lip
	Hypertermia	Score 1: body temperature > 37.3°C (99.0°F)
	Yawning	Score 1: yawning > 4 times within 3-4 hours testing period
	Nasal stiffness	Score 1: any nasal noise on breathing
	Sneezing	Score 1: sneezing > 4 times within 3-4 hours testing period
	Tachypnea	Score 2: respiratory rate > 60 breaths/minute
Enteric symptoms	Poor feeding	Score 2: difficulties in feeding for any reason (sucking impairments, positioning, muscle rigidity, etc.)
	Vomiting	Score 2: vomiting the whole feed or >2 times during feeding
	Loose stools	Score 2: liquid or a half solid and a half liquid stools
Other signs	Failure to thrive	Score 2: weight gain is > 10% below birth weight
	Excessive irritability	Score 2: infant that displays 2-3 signs of irritability (i.e. grimacing or being sensitive to touch, light and sound, gaze aversion, pull down) and it is consoled only with intervention after time; score 3: infant in which consoling did not reduce symptoms of irritability